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Glycosylation – attachment of carbohydrates to proteins – is the most prevalent form of 
post-translation modification and responsible for protein structural and functional 
diversification. These carbohydrates, also known as glycans, are ubiquitous and play key 
roles in many biological functions such as signal transduction, protein folding and quality 
control, cell recognition and pathogen invasion. Aberrant glycosylation is associated with 
major human diseases like cancer, viral and bacterial infections and neurodegenerative 
diseases. The goal of this dissertation is to develop novel experimental and computational 
tools that could provide new insights into the pathological changes of glycosylation.  A 
mass spectrometry based imaging technique is introduced for direct profiling of N-linked 
glycans from formalin-fixed paraffin-embedded tissue sections. Imaging of mouse brain 
coronal sections with this technique revealed significant differences between the 
glycomics profiles of the midbrain and brain cortex. Notably, fucosylation appeared to be 
more abundant in the cortex, while oligomannose structures and non-fucosylated glycans 
were more abundant in the midbrain. Moreover, mass spectrometry imaging of N-linked 
glycans was employed to differentiate glioblastoma tumor cells injected into a mouse 
brain from the surrounding normal tissue. To examine the protein hosts of glycans and 
the microheterogeneity of glycosylation, an algorithm and accompanying software tool 
were developed for site-specific identification of glycopeptides from mass spectrometry 
glycoproteomics data. Spectral library matching is introduced to assign the structures of 
intact glycopeptides based on their higher-energy collisional dissociation fragmented 
tandem mass spectra. Taking advantage of the power of spectral library matching, novel 
glycan modifications were exposed. Machine learning was applied to the spectral features 
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of glycopeptides to predict their glycosylation type. The application of the developed 
software tool, named GPQuest, was verified on recombinant glycoproteins and employed 
to study complex samples like prostate cancer cell lysates. GPQuest, powered with an 
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Chapter 1.    Introduction 
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1.1    Overview 
The conventional dogma of molecular biology, which explains the template-driven 
expression of proteins from DNA molecules, is central to our understanding of how 
biological systems develop and evolve [3]. Despite being the driving force behind the 
biological revolution of the mid 20th century, this dogma tends to overlook two major 
classes of biomolecules — lipids and carbohydrates — that play critical roles in a cell’s 
normal development and survival [4] (Figure 1-1). In addition, one could argue that the 
relatively small number of genes and the great overlap between the genome of humans 
with those of other species and organisms implies that genes alone could not be 
responsible for the biological diversity that is observed in nature.  
 
Figure 1-1. Central dogma of molecular biology.  
The central dogma of molecular biology, highlighted in green, explains the flow of 
genetic information from DNA to RNA and subsequently proteins. This conventional 
view does not address the role of other major biomolecules, i.e. carbohydrates and lipids. 
In reality, many translated proteins form pathways that are responsible for biosynthesis of 
carbohydrates and lipids and assembling these biomolecules to build glycoconjugates, all 
of which play major roles in cell development and survival. 
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Protein post-translation modification (PTM) refers to covalent attachment of various 
molecules to proteins, mid- or post-biosynthesis, which affects both the structure and 
function of the host protein [5]. PTMs encompass a wide range of molecules with diverse 
chemical and physical properties and can be as small as a phosphate group in case of 
phosphorylated proteins or as large as glycosaminoglycans that are long linear 
polysaccharide chains on proteins forming proteoglycans [6]. Glycosylation is an 
enzyme-mediated PTM of carbohydrates on a modestly estimated half of the proteins and 
accounts for the highest level of protein diversification [4], [7]. Glycosylated proteins can 
be categorized into several classes depending on the structure of the carbohydrate and the 
site on which the attachment occurs. N-linked glycoproteins, O-linked glycoproteins, O-
GlcNAcylated proteins and proteoglycans are the major forms of glycosylated proteins 
[4], [8].  
Glycosylation plays a critical role in homeostasis of the cell and is involved in cell 
signaling, transcription regulation, protein folding and quality control, cell-cell and cell-
extracellular matrix interactions, bacterial and viral infections, and cancer metastasis [4], 
[7], [9]. In fact, the outer surface of all living cells is covered with a layer of glycans 
forming the glycocalyx, which is the interface of the cell with the extracellular 
environment [4], [10]. Due to this, glycosylation is particularly crucial in multicellular 
systems, were the cell-cell interactions are essential to the development and survival of 
the organism [11]. In humans, aberrant glycosylation is linked to many diseases such as 
cancer [12]–[17], cardiovascular diseases [18]–[20], immune disorders [21], [22] and 
neurodegenerative diseases [23], [24]. During the course of these diseases, dysregulation 
of the glycan biosynthesis enzymes can lead to synthesis of abnormal glycan structures 
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that not only might reveal the underlying pathological events, but also could serve as 
potential drug targets for treating the disease or as biomarkers for early detection.  
Studying glycosylation is one of the more challenging branches of molecular biology 
and chemistry owing to several factors. First, glycan structures are inherently complex. 
Unlike DNA, RNA and proteins, glycans are branched structures composed of several 
monosaccharide building units attached through glycosidic bonds. Each glycosidic bond 
has two possible stereoisomeric forms of α or β and the anomeric carbon of one 
monosaccharide can link to any of the hydroxyl groups on the second one [25]. The 
branching and diversity of linkages in glycosylation can result in complex structures, 
which pose a challenge to glycan analysis and synthesis. Furthermore, the glycan 
structure is not explicitly coded by the genome. The glycosylation machinery is utterly 
sophisticated, consisting of numerous glycosyltransferases and glycosidase enzymes that 
are encoded by more than 200 genes. The activities of these genes are affected by events 
that are specific to the cell type and development stage, not to mention the cell nutrition 
status. Glycosyltransferases and glycosidases construct the glycans by sequentially 
adding to or removing monosaccharides from the substrate. The non-template nature of 
glycosylation is an important reason why glycosylation studies have been historically 
impeded [4]. 
Glycans and glycoproteins are diverse molecules and subsequently diverse methods 
and tools are required to elucidate the structures of these biomolecules.  The analytical 
methods for study of glycans and glycoproteins can be summarized as isolation and 
identification, sometimes followed by quantification. Isolation of glycans or 
glycoconjugates can be achieved through chemical immobilization followed by 
 5
enzymatic reactions [26] and chromatographic [27], [28] or affinity-based separation 
[29]. Glycan binding proteins, also known as lectins, are a prevalent, fast and effective 
means for epitope recognition and affinity-based extraction of glycoconjugates [30]. 
High-resolution structural analysis of glycans can be accomplished by NMR and mass 
spectrometry and these methods combined with derivatization with fluorophores or mass 
labels permit quantification of the glycans or glycoconjugates [4], [25], [31].  
In recent years, there have been national and international efforts to promote the 
significance of glycosciences and the promising opportunities that it offers to research 
and patient care and to paint a roadmap as a guide for researchers in the field [9]. Scarcity 
of accessible analytical tools for glycans and glycoproteins has been identified as one of 
the obstacles for glycosciences to fully integrate with other branches of molecular 
biology [9]. The objective of this dissertation is to address some of the niches for 
analytical techniques in the field of glycosciences and provide novel tools to help 
researchers delve into glycomics and glycoproteomics. This was accomplished by 
developing experimental and computational tools for studying glycans and glycoproteins 
in simple and complex biological samples. These tools focus on mass spectrometry 
imaging techniques for direct profiling of glycans from tissue sections and bioinformatics 
methods for high-throughput site-specific analysis of glycoproteins. Applications of these 
tools are demonstrated in various biological samples, including recombinant proteins, cell 
lines, animal models and human tumor cells. 
1.2    Organization of the thesis 
The organization of this thesis is as follows: Chapter 2 provides an overview of protein 
glycosylation, and structural diversity, functional roles of glycosylation and significance 
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of glycosylation in human health. Chapter 3 presents the technologies and methods that 
are used for analysis of glycosylation with emphasis on mass spectrometry techniques. 
These two introductory chapters intend to provide the reader with sufficient background 
on glycosylation and present the concepts and nomenclature that is used in this 
dissertation. 
Chapter 4 presents a mass-spectrometry based technique for imaging the distribution 
of N-linked glycans on formalin-fixed tissue sections. This technique permits high-
throughput imaging of tens of glycans in one single experiment with superb specificity. 
Application of this imaging technique on mouse brain section revealed clear distinctions 
between the glycosylation patterns in midbrain versus the cortex. In addition, mass 
spectrometry imaging was used to differentiate tumor cells injected into healthy mouse 
brain in this study. 
Chapter 5 and 6 focus on computational algorithms and software tools for high-
throughput analysis of mass spectrometry glycoproteomics data. In chapter 5, spectral 
library matching is introduced for assignment of tandem mass spectra to intact N-
glycopeptides structures and the application of this algorithm in analyzing cell lysate 
extracts of LNCaP prostate cancer cells is demonstrated. In chapter 6, the 
glycoproteomics algorithms are extended to include O-glycoproteins as well as N-
glycoproteins.  This was achieved by combining the spectral features of tandem mass 
spectra with machine learning to predict the glycosylation type for each tandem mass 
spectrum. Furthermore, GPQuest is introduced in this chapter, which is a software 
package developed in conjunction with this project for glycoproteomics analysis of 
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higher-energy collisional dissociation fragmented data of glycoprotein mixtures and 
biological samples.  
Chapter 7 concludes this dissertation by providing preliminary data on the relevant 








Chapter 2.    Background – Protein 




Glycans are sugar chains and branched assemblies of monosaccharides that are post-
translationally attached to more than half of the total human proteins and mediate their 
function. They coat the surface of all living cells, controlling their interactions with the 
extracellular environment through cell signaling and recognition. According to the central 
dogma of molecular biology, genes are first transcribed to RNA sequences, which in turn 
are translated to proteins. For proteins however, this is just the beginning. They further 
mature during protein folding, are modified by an array of post-translational 
modifications (PTM) and go through a quality control process. Glycosylation is the most 
prevalent form of PTM and affects the majority of the proteins. This chapter provides an 
overview of protein glycosylation, its functional roles and significance in human health 
and disease. 
2.1    N-linked and O-linked protein glycosylation 
The most common forms of protein glycosylation can be categorized into N-linked and 
O-linked classes. N-linked glycosylation occurs on NXS, NXT, and less commonly NXC 
and NXV sequences [32], where X can be any amino acid except proline. N-glycans have 
a common core of two N-acetylglucosamine (GlcNAc) and three mannose residues and 
can be subdivided into oligomannose, complex and hybrid structures as shown in Figure 
2-1 [4]. N-glycosylation is particularly common on secreted and membrane-bound 
proteins on cell surface [33]. O-linked glycosylation occurs on S, T or less commonly Y 
residues on proteins [34]. O-glycan structures are more diverse than N-glycans and 
include subclasses of O-GalNAc, O-fucose and O-mannose, where for O-GalNAc – also 
known as mucin-type — glycans alone, 8 core structures have been observed [4]. Mucin-
type glycoproteins, which are found in excess in mucous, contain S/T rich regions that 
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are heavily O-glycosylated. These regions usually are rich in proline as well, which 
subsequently facilitates the O-glycosylation of S/T residues [35]. Mucin-type 
glycoproteins are believed to provided immunity against pathogens by serving as decoys 
to their lectin receptors [36]. Both N- and O-linked glycosylation happen in Golgi and 
Endoplasmic Reticulum [8]. N-linked and O-linked glycans are usually adorned with 
fucose or sialic acid residues on the core GlcNAc or on the elongated branches, which 
facilitate the recognition of glycoproteins by lectins and antibodies [37]. Another form of 
protein glycosylation, called O-GlcNAcylation, is the attachment of a GlcNAc to the S or 
T residues on proteins by the O-GlcNAc transferase (OGT) enzyme and can happen in 
cytoplasm, nucleus or mitochondria. O-GlcNAcylation is a dynamic modification in 
nature and can be reversed by detachment of the GlcNAc from the peptide using the O-
GlcNAcase (OGA) enzyme, which makes the S or T residue available for another 
potential round of modification by a phosphate group or GlcNAc [38]. Proteoglycans are 
another form of glycosylated proteins and constitute proteins linked to long chains of 
glycosaminoglycans via a xylose residue [6].  
Figure 2-1. Types of N-glycans.  
N-linked glycans are connected to the 
asparagine residue on the protein 
backbone via an N-glycosidic bond. 
Typically, N-linked glycan structures 
can be sorted into oligomannose, 
complex or hybrid. (Reprinted from 
‘Essentials of Glycobiology’, Cold 
Spring Harbor Laboratory Press [4] 
with permission. Copyright © 2009, 
The Consortium of Glycobiology 
Editors, La Jolla, California) 
 
 11
Dissimilar to proteins that fold inward, resulting in burying parts of the protein backbone, 
glycans tend to extend outward and occupy space. Considering the fact that glycans are 
large molecules oftentimes comparable in mass and size to their host peptide sequences, 
modification of proteins by glycans affects their 3-dimensional (3D) structure and 
consequently, their activity. They carry much of the information content of living systems, 
thus relating the genomics data with the observed phenotype [9]. A membrane-bound 
glycoprotein modified by N-linked and O-linked glycans is shown in Figure 2-2 [39]. To 
facilitate the illustration of glycans, each monosaccharide is represented by a shape and 
the key is provided in this figure. This thesis follows the standard presented in Figure 2-2. 
 
 
Figure 2-2. Schematic of a glycoprotein modified by N-linked and O-linked glycans.  
Monosaccharides are building blocks of glycans and depending on their chemical composition 
and 3D structure, are represented by different shapes. (Reprinted from ‘Protein-glycan 
Interactions in the Control of Innate and Adaptive Immune Responses’, Nature Immunology 9, 
593- 601 (2008) [39] with permission. Copyright © 2008, Rights Managed by Nature Publishing 
Group) 
  






N-Acetylneuraminic acid (Neu5Ac) 
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Unlike proteins, structures of glycans are not explicitly coded by the genome. In fact, 
protein glycosylation is determined by proteins involved in glycan biosynthesis pathways 
whose activities are affected by protein abundance and cell type-specific events. In 
addition, glycosylation at a specific glycosylation site is regulated by other factors such 
as substrate glycoprotein abundance, protein folding, cell type and its development and 
metabolic state. These factors result in what is called the microheterogeneity of 
glycosylation, where the occupancy of identical protein glycosylation sites by different 
glycan structures varies and each protein can be found in several diverse glycoforms [4], 
[40], [41]. Microheterogeneity plays key roles in the function of this post-translational 
modification [40], [42], [43] and therefore the ability to preserve this information is 
critical. For example, increased sialylation of glycans on IgG affects its anti-
inflammatory properties [44]. Moreover, numerous studies have shown that during the 
progression of diseases, both glycans and glycoproteins can go through changes in their 
structures and abundance, suggesting that in fact changes in glycans or glycoproteins are 
not independent from each other [11], [40], [42], [45]. Therefore, site-specific 
glycoproteomics analysis could potentially lead to identification and characterization of a 
new class of biomarkers that are more specific to their underlying pathology, similar to 
fucosylated alpha-fetoprotein for detection of liver cancer [46]. For example, metastatic 
prostate cancer cells exhibit higher levels of fucosylation. However, this increased 
fucosylation occurs in a site-specific manner such that even glycosites on the same 
protein are affected differently in response to elevated levels of fucosyltransferase 
enzymes [47]. The ability to monitor the changes in the microheterogeneity of 
glycosylation induced by different pathological conditions is critical for diagnosis and 
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treatment. In addition, this topic is of particular interest in developing antibodies against 
glycoproteins and in the field of vaccine development [48].  
2.3    Significance of glycosylation to human health 
Glycans play vital roles in almost all biological processes (Figure 2-3 [7]), e.g. 
transcription regulation, cell proliferation, cell signaling, cell-cell and cell-extra cellular 
matrix interactions, bacterial and viral infection, protein degradation, inflammation and 
activation of the immune system [4], [7], [8]. Yet, the extent of damage imposed on the 
cell or organism as a result of specific alterations in glycosylation depends highly on 
factors like cell type, developmental stage and whether the experiment is in vivo or in 
vitro, and can vary from being undetectable to fatal [11]. For example, while knock down 
of GlcNAcT-1 glycosyltransferase gene is tolerated in cell lines, it exhibits severe 
phenotypes in mouse models [49].  
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Figure 2-3. Functional roles of glycosylation. 
Glycosylation in intertwined with almost all cellular functions from regulating the transcription to 
protein quality control, cell signaling and cell interactions with other cells or the extracellular 
environment. (Reprinted from ‘Glycomics Hits the Big Time’, Cell 143, 672–676 (2010) [7] with 
permission. Copyright © 2010 Elsevier Inc.) 
 
Glycans are involved in almost all diseases that affects humans such as cancer, 
cardiovascular diseases, neurodegenerative diseases and disorders of immune system as 
observed and confirmed in numerous studies [4], [7], [11], [40], [50]–[52]. In cancer, 
abnormal glycosylation is a universal feature observed in many cancer cell types and 
tissues such as prostate, breast, ovarian, lung and liver cancers [12], [53]. Some of the 
most widely used clinical assays for cancer screening and diagnosis aim at detection of 
glycosylated proteins, among which are prostate-specific antigen and cancer antigen 125 
[53]. The glycosylation profile of the cell undergoes changes during tumor formation and 
metastasis. For example, aberration in the cell surface glycans leads into more aggressive 
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cellular behavior and cancer progression and presence of truncated O-glycans on the cell 
surface is linked to aggressive cancer [15], [54]. Congenital disorders of glycosylation 
(CDG) are a class of inherited disorders caused by genetic mutations that result in 
defective glycosylation machinery or metabolism [55]. CDGs are very rare because they 
are oftentimes fatal in early development, and in case of survival, lead to severe 
phenotypes in childhood and early adulthood. In the immune system, lectins on the cell 
surface are capable of recognizing foreign glycans from bacteria and pathogens, thus 
protecting the cell from infection. Likewise in autoimmune disorders, deficiencies in the 
glycosylation biosynthesis pathway may construct abnormal and potentially 
immunogenic glycan epitopes [11] that provoke an immune response from the cell 
surface lectins. Glycans are also critical to endocytosis and cell trafficking. Therefore, 
deficiencies in glycosylation could disturb transportation of defective proteins and 
glycans to lysosome for degradation, resulting in cellular storage diseases [11].  
Every year, more diseases are discovered to be attributed to deficiencies in 
glycosylation. Diagnosing diseases of glycosylation and understanding their biology has 
saved many patients from severe symptoms and improved their quality of lives. For 
example, a treatment as simple as taking oral mannose supplements alleviates the life-
threatening symptoms of CDG-1b patients [56]. Expanding the toolbox of researchers in 
glycosciences is an essential step that could help reveal better diagnostics and therapeutic 





Chapter 3.    Background – Overview of 




The past decade has witnessed dramatic progress in development of analytical tools and 
methods for studying glycosylation from biological sources. The glycosciences have 
greatly benefited from years of experience in protein analytics and many of the 
glycoproteomics analytical methods have originated from proteomics. Even though 
protein analytics have offered glycosciences a fundamental toolbox, numerous challenges 
remain unresolved. Since the complexity of glycans and glycoproteins surpasses that of 
proteins, additional analytical techniques tailored to these biomolecules are required. This 
chapter presents an overview of the existing technologies that are used for analysis of 
glycans and glycoproteins as well as the niches that offer opportunities for innovation and 
growth. 
3.1    Experimental analytical tools for glycans and glycoproteins 
Analysis of glycans and glycoconjugates starts with isolation of these analytes from the 
biological sources to improve the detection sensitivity and minimize interference from 
other analytes. Isolation and purification of glycoconjugates is followed by detection, 
identification and if applicable, quantification of these analytes [25], [31]. Lectins, solid 
phase extraction, endo- and exoglycosidases, nuclear magnetic resonance, 
chromatography, and mass spectrometry are among the most common techniques for 
isolation, detection and identification of glycans and glycoproteins. 
3.1.1    Lectins 
Lectins are naturally occurring glycan-binding proteins that recognize certain glycan 
epitopes with great specificity [30], [57]. Lectins are inexpensive and easy to use and 
therefore one of the most ubiquitous reagents for glycan analysis. They are commercially 
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available in different forms such as native, biotinylated for lectin histochemistry analysis, 
agarose-conjugated for immunoprecipitation and fluorophore-conjugated for microscopy 
and cytometry of glycans and glycoconjugates. In addition, lectin microarrays have been 
developed for quick and high-throughput glycan profiling and biomarker screening of 
multiple samples [58], [59]. Besides being inexpensive and easy to use, lectins are 
capable of differentiating glycan isomers and linkage types, which is a major hurdle in 
glycan structural analysis. For example, while it is not straightforward to distinguish 
different hexose sugars using mass spectrometry, concanavalin A (ConA) and ricinus 
communis agglutinin (RCA) bind mannose and galactose, respectively and can be used to 
tell them apart [30]. Lectins are versatile tools for glycan analysis, but they have certain 
limitations. Each lectin recognizes certain epitopes; consequently two different 
glycoforms sharing the same epitope cannot be distinguished using lectins alone. This 
property necessitates the application of additional orthogonal methods such as mass 
spectrometry, when detailed structure of the whole glycan or glycoconjugates is of 
significance. 
3.1.2    Solid phase extraction of glycans and glycoproteins 
Solid phase extraction has been applied for isolation of glycans and glycoconjugates to 
great effect [60]–[63]. In this method, glycoproteins are chemically immobilized on solid 
beads conjugated to functional groups e.g. carboxyl, aldehyde or amine groups via the 
glycan end, protein termini or protein side chains. The flexibility of the solid phase 
extraction technique allows for isolation of glycans or glycosite-containing peptides. For 
example, to analyze the glycan portion, Yang et al conjugated the N-termini of 
glycoproteins via reacting the protein amine groups with aldehydes on the bead surface 
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[26], [29]. On the contrary when the sequence of the glycosite-containing peptide is of 
interest, the glycoproteins can be conjugated on solid support on their glycan end by 
reacting the oxidized glycans to hydrazide functional groups on the beads, leaving the 
glycosite free for further enzymatic digestion [61], [63].  
Solid support extraction retains the sample during clean up, thus minimizing sample 
loss and improving the sample preparation efficiency. Glycans are regularly derivatized 
with mass tags for quantification, or esterified or permethylated for sialic acid 
stabilization or linkage analysis [60], [64], [65]. Although derivatization is an integral 
part of glycomics analysis, it can result in contaminations and/or sample loss. 
Immobilization of glycoconjugates on solid phase allows for straightforward clean up 
after derivatization of the glycoconjugates and minimizes the sample loss due to washing 
steps, because the glycoproteins are attached to the solid support via a covalent bond. 
Following the sample clean up, glycans or glycosite-containing peptides of interest are 
released by enzymatic or chemical reactions, collected and purified for identification. 
3.1.3    Endo- and Exoglycosidases  
When the objective of a glycomics study is to analyze intact carbohydrates, the glycans 
can be released from glycoproteins using enzymatic or chemical reactions or a 
combination of both. Peptide-N-glycosidases are enzymes that cleave off the N-linked 
glycans from their host protein without breaking the glycosidic bonds between the 
monosaccharides. Due to lack of universal enzymes for release of O-linked glycans en 
bloc, alternative chemical reactions like beta-elimination or hydrazinolysis can be used 
instead [31]. Moreover, to attain detailed structural features of the glycans e.g. sugar 
isomers and linkage anomericity, single monosaccharides can be sequentially released 
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using exoglycosidase enzymes. Exoglycosidases remove the terminal monosaccharide 
from the glycans with superb specificity to not only the sugar type but also the linkage. 
Sequential treatment with an array of exoglycosidases is oftentimes combined with 
chromatography or electrophoresis for sequencing the glycan structure [66]. 
3.1.4    Nuclear magnetic resonance spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a non-destructive technique for 
characterizing the structure of glycans and glycopeptides [67]. NMR spectroscopy 
provides extensive details about the structure of glycans. In particular, NMR is capable of 
revealing the anomericity of the examined monosaccharides [4] and is an effective tool 
for probing glycan-protein interactions. NMR spectroscopy requires milligrams of 
purified sample for operation, which is difficult to achieve, particularly in clinical 
samples. The low sensitivity of NMR is therefore the main hurdle in broad application of 
this technique. Nano-NMR probes are improved implements that could be used for 
analyzing few nano-moles of purified samples [67]. 
3.1.5    Chromatography 
Owing to the complexity of glycan and glycoprotein samples, low abundance of 
glycoconjugates and diversity of glycan isomers, separation techniques are usually 
required to improve the detection sensitivity [68]. Liquid chromatography is routinely 
used for separation of glycans and glycopeptides.  
Hydrophilic interaction chromatography (HILIC) takes advantage of the hydrophilic 
nature of glycans and glycopeptides to retain these analytes on the polar stationary phase. 
The glycans or glycopeptides are eluted from hydrophobic to hydrophilic using high to 
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low gradients of acetonitrile solutions [27], [28], [43], [69]. Porous graphitized carbon 
(PGC) is another type of support commonly used for purification and separation of 
glycans and glycopeptides [28], [29], [70].  PGC offers broad working pH range, stability 
at high temperatures and is chemically non-reactive [68]. Consequently, it is a practical 
tool in harsh experimental conditions. Reverse-phase chromatography is typically used 
for separation of glycans that have become more hydrophobic due to labeling with 
fluorescent tags [31], [71]. Glycans do not absorb ultraviolet light; therefore labeling 
glycans with fluorescent tags improves their limit of detection. Labeling kits for these 
tags, for example 2-aminobenzoic acid, 2-aminobenzamide and 3-(acetylamino)-6-
aminoacridine, are commercially available. 
Chromatographic separation usually precedes mass spectrometry analysis of glycans 
and glycoproteins [71]. However, it could also serve as a means to identify the glycans 
and characterize their structure. The retention time of glycans on a given column can be 
estimated as a function of their structural properties and number of monosaccharides [72]. 
Alternatively, comparing the results with a library of chromatograms of known glycan 
standards would help in characterizing the glycan.  
3.1.6    Mass spectrometry  
Mass spectrometry is a powerful and sensitive high-throughput tool for analysis of 
glycans and glycoproteins, achieving a limit of detection down to the attomole range. 
High resolution mass analyzers such as time-of-flight (TOF) and orbitrap in combination 
with tandem mass spectral analysis provide superb specificity. Mass spectrometry 
approaches commonly follow the liquid chromatography separation of glycoconjugates 
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samples and can be applied for quick profiling as well as detailed structure determination 
of glycans and glycoproteins.  
Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) is one of 
the most common ionization techniques in glycomics applications [73], [74]. In MALDI 
mass spectrometry, glycans or glycoproteins are covered with a matrix such as α-cyano-
4-hydroxycinnamic acid (CHCA) or 2,5-dihydroxybenzoic acid (DHB) and air-dried. The 
matrix absorbs the laser energy and transfers it to the analytes, thus creating a soft 
ionization effect, which protects the glycans or glycopeptides from unwanted 
fragmentation. MALDI creates predominantly singly charged ions and therefore the mass 
spectra generated by this technique are relatively straightforward to analyze. MALDI 
ionization often results in loss of sialic acid and therefore sialylated glycans are often 
permethylated or derivatized before MALDI-MS [65], [75]. MALDI ionization is 
routinely coupled to time-of-flight mass analyzers. MALDI-TOF/TOF instruments are 
particularly successful for analysis of high molecular weight biomolecules including 
glycans and glycoproteins [76]. MALDI-MS has been effectively applied for glycomics 
analysis in numerous studies [76]–[81]. 
Electrospray ionization (ESI) is another technique commonly used for analysis of 
glycans and particularly glycopeptides [74]. In ESI, high voltage is applied to the solution 
creating a fine spray of charged droplets, which turn into gaseous phase that contain the 
ions [82]. ESI creates ions bearing multiple charges, leading to more complicated mass 
spectra. So, analyzing the mass spectra generated by ESI usually requires more effort. 
Nano-ESI with high mass resolution analyzers such as orbitrap is particularly common 
for analysis of glycopeptides [43], [83]–[85]. Ion traps are also integrated in these mass 
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spectrometers for improving MSn analysis by trapping enough ions for high quality 
fragmentation [76]. 
Tandem mass spectrometry analysis is key in identification of glycans and 
glycopeptides using mass spectrometry. Depending on its mechanism of action, 
fragmentation of glycans and glycopeptides reveals unique details about the structure of 
precursor ions. Several fragmentation techniques have been utilized in glycomics studies, 
such as electron transfer dissociation (ETD) [74], [86], [87], collision induced 
dissociation (CID) [78], [88], [89] and higher-energy collisional dissociation (HCD) [43], 
[47], [90], [91]. These methods often provide complementary information about the 
structure of glycans and glycopeptides. For example, ETD results in breaking the peptide 
bonds in the glycopeptide structures leaving the post-translation modifications intact. 
Therefore, it is an effective tool for creating the fingerprint of the peptides and 
determination of the modification sites. In contrast, CID breaks glycosidic bonds, 
generating glycan fingerprints and therefore is ideal for detailed structural analysis of the 
glycan portion of the glycopeptide. HCD results in partial fragmentation of both the 
peptide and glycosidic bonds. Typically, multiple fragmentation methods work in tandem 
for complete structural determination of glycopeptides [86], [89], [92]. 
3.2    Mass spectrometry based glycoproteomics 
High-throughput investigation of glycosylation is oftentimes accomplished through mass 
spectrometry analysis. Until a few years ago, these studies mainly involved enrichment or 
isolation of glycopeptides using hydrazide chemistry, lectin affinity techniques or 
hydrophilic interaction chromatography, followed by detaching the glycan portion from 
the protein using chemical or enzymatic methods. The glycans and glycosite-containing 
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peptides were then isolated and examined separately [63], [70], [78], [93], [94], which led 
to loss of the microheterogeneity information of glycosylation. 
In the past few years, advances in mass spectrometry techniques and instrumentation 
have made it possible to study and identify intact glycopeptides from recombinant 
proteins, glycoprotein cocktails or complex biological samples such as cells, serum and 
tissues [2], [43], [91], [95]–[99]. In shotgun glycoproteomics, the glycoprotein extract is 
digested using protease enzymes, most commonly trypsin. The resulting mixture of 
peptides and glycopeptides is separated using high-performance liquid chromatography 
(HPLC) and the eluted analytes are ionized and analyzed by mass spectrometry. For 
tandem MS analysis, certain mass spectral peaks are purified in the gas phase for 
fragmentation to generate fragment ions from specific precursor ions. The subsequent 
tandem mass spectra represent glycan specific fingerprints. While traditional ion trap 
mass analyzers have suffered from a low mass cutoff that obscured the low m/z region, 
newer Orbitrap analyzers have overcome this limitation. This is of particular importance 
in analyzing HCD fragmented glycopeptides, where detection of low mass 
monosaccharide ions is crucial for identification of glycopeptides. The significance of 
these advances is that for the first time, we are able to preserve and study the 
microheterogeneity of glycosylation in a high-throughput manner, meaning that not only 
can we characterize and quantify the glycosite-containing peptides and glycans, but we 
can also scrutinize glycosylation in a site-specific manner. On one hand, the 
advancements in technologies have enabled us to study the microheterogeneity of 
glycosylation in a high-throughput fashion. On the other hand, these instruments are 
capable of generating data at rates as high as 1 gigabyte/hour resulting in massive 
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amounts of glycoproteomics data being accumulated. Development of software tools and 
algorithms for high-throughput interpretation of glycoproteomics data is an open area of 
research. Database search and precursor mass matching, spectral library matching, and 
less commonly de novo sequencing can be used to assign the tandem mass spectra of 
fragmented glycopeptides to their corresponding structures [100]. Different 
fragmentation mechanisms generate distinct glycopeptide tandem spectra and therefore 
require specifically designed algorithms. For example, CID breaks the glycosidic bonds 
of the glycan portion, whereas ETD breaks the peptide bonds instead, resulting in very 
different tandem mass spectra representing the same glycopeptide structure. These 
patterns must be taken into account when designing or choosing algorithms for analysis 
of glycoproteomics data. Glycoinformatics has made great strides in the past decade and 
the glycobiology field has experienced an outburst in the number of software tools for 
automated identification and analysis of glycan and glycoconjugates from different data 
sources. Integration of bioinformatics tools into glycomics and glycoproteomics 
platforms has been instrumental in taking advantage of the advances in biotechnology 
and instrumentation. The most recent software tools for glycoproteomics are thoroughly 
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4.1    Summary 
Aberrant glycosylation is associated with most of the diseases. Direct imaging and 
profiling of N-glycans on tissue sections can reveal tissue-specific and/or disease- 
associated N-glycans, which not only could serve as molecular signatures for diagnosis 
but also shed light on the functional roles of these biomolecules. Mass spectrometry 
imaging (MSI) is a powerful tool that has been used to correlate peptides, proteins, lipids, 
and metabolites with their underlying histopathology in tissue sections. Here, we report 
an MSI technique for direct analysis of N-glycans from formalin-fixed paraffin-
embedded (FFPE) tissues. This technique consists of sectioning FFPE tissues, 
deparaffinization, and rehydration of the sections, denaturing tissue proteins, releasing N-
linked glycans from proteins by printing peptide-N-glycosidase F over the sections, 
spray-coating the tissue with matrix, and analyzing N-glycans by matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI-MS). Brain sections from a C57BL/6 
mouse were imaged using this technique at a resolution of 100 μm. Forty-two N-glycans 
were analyzed from the mouse brain section. The mass spectrometry images were used to 
study the relative abundance of oligomannose, nonfucosylated, and fucosylated complex 
N-glycans in different brain areas including isocortex, hippocampal formation, and 
brainstem and specific glycans associated with different areas of the brain were identified. 
Furthermore, glioblastoma tumor xenografts in a NOD/SCID mouse were imaged. 
Several glycans with differential expression in tumor versus normal brain tissues were 
identified. The MSI technique allows for imaging of N-glycans directly from FFPE 
sections. This method can potentially identify tissue-specific and/or disease-associated 
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glycans coexpressed with other molecular signatures or within certain histological 
structures.  
4.2    Introduction 
Imaging of tissue N-glycans is an essential, yet less-explored tool for studying their 
functions. In contrast to conventional glycan profiling assays, where the tissue is first 
homogenized, imaging focuses on studying the glycosylation heterogeneity in 
pathologically or structurally different regions of the tissue. Therefore, it can provide an 
invaluable means to understanding the roles of N-glycans in the physiology and 
molecular pathology of the diseases. 
Histochemical staining using lectin is by far the most common method for 
visualization of glycosylation from formalin-fixed paraffin-embedded (FFPE) tissue 
sections. For instance, Concanavalin A (ConA) and Aleuria Aurantia Lectin (AAL) are 
two of the lectins that are used in histostaining of oligomannose and fucosylated glycans, 
respectively [30]. Despite its contributions to the studies on glycosylation in pathological 
tissue sections, this technique is limited in many ways. First, lectins provide minimal 
structural information about the stained epitopes. For example, ConA can bind internal 
and non-reducing terminal α-mannose [101], thus staining a variety of oligomannose 
structures. Therefore, the ConA staining cannot specify the structure of the glycans. In 
addition, they often fail to differentiate between different glycan subgroups. For instance, 
AAL can bind the fucose residues on both N-linked and O-linked glycans. Second, due to 
steric hindrance of different glycan epitopes, lectin histostaining is limited to very few 
lectins at a time on each tissue section, thus making multiplex glycan imaging very 
challenging. Third, histostaining methods lack quantification accuracy. Compared to the 
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lectins, glycan antibodies are more specific with respect to the glycan determinants. 
However, the number of currently developed monoclonal antibodies for glycans is far 
from covering the width of the mammalian glycans [9]. Therefore, alternative imaging 
techniques are essential to complement the information acquired from histostaining 
assays.  
Mass spectrometry imaging (MSI) has been previously applied for spatially-resolved 
profiling of proteins, lipids, small molecule metabolites and drugs from tissue sections 
[102]–[106]. Owing to the high sensitivity and specificity of mass spectrometric analysis, 
MSI has overcome some of the challenges of conventional histostaining techniques. 
Unlike affinity-based detection methods such as immunohistochemistry staining, where 
the detection relies on some understanding of the analyte of interest, MSI does not 
require any a priori knowledge of the glycans. This attribute, which is a unique 
characteristic of MSI, is particularly desirable for discovery research. In addition, 
hundreds of analytes can be detected and identified from one single mass spectrometry 
experiment, resulting in high-content molecular profiling with spatial information in 
tissue sections. Furthermore, MSI can be combined with quantitative and semi-
quantitative mass spectrometry analysis techniques to facilitate quantitative imaging of 
different analytes directly from tissue sections. The recent advances in mass spectrometry 
techniques and data interpretation have significantly pushed the limits of glycomics 
studies [107]. However, the low ionization efficiency of native glycans compared to other 
macromolecules such as proteins and lipids makes them challenging to study in complex 
mixtures. Therefore, glycans are often isolated from extracts of biological samples and 
chemically modified, e.g. permethylated, before mass spectrometry analysis [108], [109]. 
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In this glycomics procedure, the spatial information of glycans is lost due to 
homogenization of the sample. Recently, we demonstrated that glycans released from 
glycoproteins that were immobilized on a solid phase could be directly analyzed by mass 
spectrometry. This method does not require further purification of glycans to remove 
interferences from proteins and peptides [26], [29]. This attribute is crucial for 
development of a glycomics study platform for imaging of glycans from samples with the 
high biological complexity of the tissues.  
In this study, we developed a mass spectrometry-based platform for imaging of N-
linked glycans from formalin-fixed paraffin-embedded (FFPE) tissue sections. In this 
technique, FFPE tissue sections are mounted on glass slides, which results in 
immobilization of the tissue glycoproteins on the slides. N-linked glycans are then 
selectively released from glycoproteins of tissue section by applying PNGase F enzyme 
using a microarray printer. The matrix-coated slides are subsequently analyzed by 
MALDI-MS. The acquired mass spectral images show the distribution of the N-linked 
glycans over the tissue section. Imaging of the N-linked glycans from FFPE coronal 
mouse brain tissue sections using this method revealed the spatial distribution of 42 N-
linked glycans. In addition, the results showed that N-glycans are present in all regions of 
the brain. However, certain modifications are more abundant in particular brain structures. 
For example, brainstem (BS) is richer in oligomannose and non-fucosylated complex N-
glycans, while the majority of the fucosylated N-glycans are more abundant in isocortex 
(IsoCTX) and the hippocampal formation (HPF). These observations were also compared 
with histostaining of adjacent tissue sections with AAL and ConA lectins. In addition, 
glioblastoma brain tumor xenografts from a NOD/SCID mouse were imaged by MALDI-
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MS. Based on the acquired ion images, several N-glycans with differential expression in 
tumor versus adjacent normal tissues were distinguished, most of which were more 
abundant in the tumor.  
The N-linked glycan mass spectrometry imaging platform not only helps identify the 
N-linked glycans directly from FFPE tissue sections, but also determines the spatial 
distribution of unique glycan structures over the tissue.  This technique provides 
complimentary information to the traditional histostaining methods, which is essential to 
fully characterize the functional and pathological roles of N-linked glycosylation in 
tissues.  
4.3    Methods 
4.3.1    Materials and reagents 
Antigen retrieval buffer was purchased from R&D Systems (Minneapolis, MN). Peptide-
N-Glycosidase F (PNGase F) was from New England Biolabs (Ipswich, MA), 
Dithiothreitol (DTT), Maltoheptaose (DP7), 2,5-dihydroxybenzoic acid (DHB) and N,N-
Dimethylaniline (DMA) were purchased from Sigma Aldrich (St Louis, MO). 
Biotinylated AAL and ConA lectins and the ABC-Elite kit were from Vector Labs 
(Burlingame, CA).  Peroxidase blocking reagent was from Dako (Glostrup, Denmark). 
4.3.2    Animal methods 
A male C57BL/6 mouse from Jackson Laboratory (Bar Harbor, ME) was used for this 
study. It was housed in an animal facility with access to water, food and libitum. The 
mouse was euthanized at 20 weeks of age by harvesting organs and tissues: heart, aorta, 
kidney, liver, brain and spleen, under anesthesia with Ketamine/Xylazine (100mg/10mg 
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per kg IP). For imaging of the mouse brain tumor using MALDI mass spectrometry, 106 
primary human glioblastoma cells (NS276) were stereotactically injected into the right 
striatum of an 8-week old, NOD/SCID male mouse (Charles River Laboratories) as 
previously described [110]. Four weeks following the tumor implantation, the mouse was 
sacrificed and the brain was extracted. These experiments were approved by the Johns 
Hopkins University Institutional Animal Care and Use Committee (Protocol numbers 
MO11M492 and MO12M195). 
4.3.3    Mouse brain tissue fixation and embedding 
The mouse brain tissues were fixed in 10% formalin for 48 hours after dissection. 
Following dehydration, the fixed brain tissues were embedded in paraffin. The samples 
were sectioned at thickness of 5 μm. The normal brain tissue sections were mounted on 
indium tin oxide (ITO) coated glass slides (Delta’s Technologies, Loveland, CO), while 
the tumor brain sections were mounted on positively charged glass slides. The slides were 
stored at room temperature for a maximum of one month until use.  
4.3.4    Tissue preparation 
The FFPE tissue sections were deparaffinized by 3 xylene washes, 15 minutes each. 
Subsequently, they were rehydrated in graded ethanol solutions of 100, 95, 70 and 50%. 
To denature proteins on tissue slides, antigen retrieval procedure was performed by 
baking the tissue sections in the basic antigen retrieval buffer, pH 9.0 (R&D Systems) for 
20 minutes. This was followed by protein denaturing in 40 mM DTT buffer and steaming 
for 10 minutes.  Pretreatment of the tissue with denaturing reagents improves the 
deglycosylation significantly. The tissue was then briefly washed with 1% formic acid, 1 
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M sodium chloride and deionized water. The tissue was further washed with 15 mM 
ammonium bicarbonate buffer (pH ~8.0) for 20 minutes to equilibrate the pH of the 
section before applying the PNGase F enzyme. One additional section was prepared 
using this method to serve as the no enzyme control. 
4.3.5    Deglycosylation and matrix deposition 
PNGase F is the enzyme that cleaves the N-linked glycans from the attached proteins and 
peptides. 1 M ammonium bicarbonate buffer was added to PNGase F to bring the final 
pH to 8, close to the optimal pH for deglycosylation by PNGase F. 1mM DP7 was spiked 
into the enzyme solution as an internal standard to obtain a final concentration of 70 μM. 
PNGase F mixture was printed over the tissue section using an automated microarrayer 
(BioRobotics MicroGrid, Isogen Life Science, De Meern, The Netherlands) at 200 μm 
spacing. The robotic application of the enzyme using the microarray printer not only 
creates a uniform array of localized enzyme over the tissue, but also requires significantly 
less amount of PNGase F. The PNGase F-printed tissue section was incubated in a 
humidity chamber (maximum humidity of 80%) at 37°C overnight. The matrix was 
prepared by dissolving 120 mg of DHB into 1 mL of 50% acetonitrile, 0.1 mM sodium 
chloride followed by addition of 20 μL of DMA. The matrix solution was uniformly 
sprayed over the sample using an artistic airbrush (Aztek 470, Testors, Rockford, IL) 
according to the method previously described [111]. 
4.3.6    MALDI imaging 
After the sample was air-dried, it was analyzed by a MALDI-QIT-TOF mass 
spectrometer (AXIMA Resonance, Shimadzu, Kyoto, Japan). The Launchpad software 
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was used to specify the mass analysis parameters such as the mass range, the laser 
intensity, scanning area and the spatial resolution. The mass spectral images were 
acquired in positive mode with 20 shots per profile at laser intensity of 130 in the mass 
range greater than 1170 Da, by scanning the laser at a spatial resolution of 100 μm. The 
image resolution was constrained by the acquisition time. At this resolution and with the 
specified settings, it took about 11 hours to image every cm2 area of the section. The raw 
data files were converted to imaging files (.img) using the Launchpad software and the 
images were visualized and analyzed in MATLAB (Mathworks, Natick, MA).  
4.3.7    Lectin histostaining 
Followed by deparaffinization in 3 xylene washes and rehydration in graded ethanol, the 
endogenous peroxidase activity was blocked. The lectin (AAL or ConA) was diluted to a 
final concentration of 20 μg/milt in Dulbecco’s phosphate buffered saline (DPBS) and 
incubated with the tissue for 30 minutes at RT. ABC-Elite kit was used for detection of 
the biotinylated lectin according to the instructions. Diaminobenzidine was applied as the 
chromogen to visualize the tagged glycans. The tissue was then counterstained with 
haematoxylin and cover slipped. 
4.4    Results and discussion 
Mass spectrometry imaging of glycans relies on enzymatic release of N-glycans from the 
proteins that had been immobilized on the glass slide. The attachment of proteins to solid 
phase minimizes their interference with the glycan mass spectral signal. The glycan 
imaging consists of multiple steps, including deparaffinizing and rehydrating the FFPE 
section followed by antigen retrieval to recover the protein reactivity thus improving the 
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efficiency of the PNGase F digestion. After equilibrating the pH of the tissue section 
followed by air-drying, PNGase F is printed over the section in a grid at a spatial 
resolution of 100 μm using a microarrayer. The PNGase F-printed tissue is then 
incubated in a temperature-controlled humidity chamber to complete deglycosylation. 
The matrix solution is sprayed over it and the matrix-coated section is imaged by 
MALDI-MS. Figure 4-1 shows a representative schematic of the workflow for imaging 
of N-linked glycans from FFPE tissue sections. 
 
Figure 4-1. Schematic workflow of mass spectrometry imaging of N-linked glycans from 
FFPE sections.  
An FFPE tissue section is first deparaffinized and rehydrated. The tissue proteins are denatured 
by treatment with a basic antigen retrieval buffer and baking in a water bath for 20 min followed 
by incubation in a 40 mM DTT solution. To preserve the spatial information on the glycans, a 
microarray printer is used to apply the PNGase F on the tissue in a grid. The section is incubated 
in a humidity chamber at 37 °C overnight. After air-drying the tissue, DHB matrix is sprayed 
over the section using an artistic airbrush followed by analyzing by MALDI-MS. The major 
difference between a conventional MALDI analysis and an imaging experiment is that here, the 
tissue is raster scanned by the laser in the x and y directions and mass spectra are acquired for 
each pixel on the tissue. At this point, by mapping the intensity of various peaks as a function of 
location, ion images can be generated for each glycan structure detected in the mass spectra. The 
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ion image corresponding to each mass spectral peak from the MALDI-MS spectra is shown in a 
different color. 
4.4.1    Direct analysis of PNGase F-released N-glycans from FFPE tissue section 
using MALDI-MS  
To determine whether glycans could be released and directly analyzed by MALDI-MS 
from glycoproteins immobilized on conductive slides, mouse brain coronal sections were 
analyzed. PNGase F was printed over the right half of a section, while buffer was printed 
over the other half at spacing of 100 μm as a negative control. One mm2 area of each of 
the PNGase F negative and positive parts of the brain was imaged using MALDI-MS 
separately. Figure 4-2 shows the mass spectra corresponding to the PNGase F-negative 
(Figure 4-2A) and PNGase F-positive (Figure 4-2B) parts of the brain in the mass range 
of 1450 – 2400 Da. The mass spectral peaks in the bottom panel represent the N-glycans 
that are released from the glycoproteins in the PNGase F-treated section. 
 
Figure 4-2. Direct analysis of N-glycans released by PNGase F from FFPE tissue section 
using MALDI-MS.  
(A) PNGase F negative and (B) PNGase F positive. PNGase F is printed over the mouse brain 
coronal section at 100 μm spacing. The enzyme is printed on one-half of the tissue section, while 
the other half is treated with only the buffer. Mass spectra are acquired for a 1 mm2 area on each 
brain half using MALDI-MS. The mass spectrum of the PNGase F negative part shows very low 
signal, while several N-glycan peaks are detected on the PNGase F positive sample. 
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To further ensure that the mass spectral signal corresponds to the glycans, collision-
induced dissociation (CID) tandem mass spectrometry (MS/MS) was performed on the 
mass peaks in the MS1 spectrum. While not all of the mass spectral peaks were high 
enough to generate high-quality tandem MS spectra, the majority possessed the glycan 
signature mass differences of 162.05 and 203.08 corresponding to masses of a hexose 
(Hex) and N-acetylhexosamine (HexNAc) from N-glycans, respectively. The tandem MS 
spectra of two selected peaks corresponding to H7N2F0 and H4N4F1 are depicted in 
Figure 4-3 and Appendix Table 4-3. For comparison, glycomics analysis was conducted 
on mouse brain tissue extracts using glycoprotein immobilization for glycan extraction, 
which is described in detail previously [26]. The tandem MS spectra for the low-intensity 
peaks in the MALDI imaging spectra were acquired from the mouse brain extracted 
glycans to confirm their composition (Table 4-3). The fragment ions were manually 
assigned to the mass spectra with the help of the GlycoWorkbench fragmentation tool 
[112]. 
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4.4.2    Identification of N-glycans from C57BL/6 
mouse brain sections 
Analyzing the tissue section with MALDI-QIT-MS 
resulted in detection and identification of 42 N-linked 
glycans (Table 4-1), where 30 (71.4%) of them were 
fucosylated and 7 (16.7%) of them were non-
fucosylated complex glycans. All of the five 
oligomannose glycans (Man5, Man6, Man7, Man8, 
and Man9), constituting the 11.9% of the detected 
glycans, were identified. A list of the detected 
glycans is given in Table 4-1, where each N-glycan is 
depicted by its number of hexose (H), N-
acetylhexosamine (N) and fucose (F) residues.  The 
glycan composition identification was performed by 
first matching the peak mass with a database of all 
possible mammalian N-glycan compositions, and 
then refined by comparing the results with the 
Consortium for Functional Glycomics databases and 
the literature to remove the biologically irrelevance 
matches. Last, the glycan composition assignment 
was confirmed by evaluating the corresponding 
tandem MS spectra. Fucosylation could happen at the core or at the non-reducing ends of 
the glycans. Heavier, more branched glycans were generally lower in abundance and 
Figure 4-3.  Examples of CID 
tandem MS spectra of the 
detected glycan peaks.  
(A) H7N2F0 and (B) H4N4F1. 
Mass differences of 162.05 and 
203.08 in tandem MS spectra are 
characteristic of glycans, which 
occur due to loss of Hex and 
HexNAc. The fragment ions are 
assigned to the mass spectra using 
the GlycoWorkbench tool. The 
acquired tandem MS spectra further 
support the specificity of this 
imaging technique to N- glycans. 
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harder to detect. The largest identified N-linked glycan was a highly branched structure 
with [M+Na]+ theoretical mass of 2669.967 Da. In this experiment, however, sialylated 
glycans were missing from the spectrum. One possible explanation for this observation is 
the loss of sialic acid residues during mass spectrometry analysis by MALDI [81], [113]. 
The identified glycans were compared with mouse brain glycans reported on the 
Consortium for Functional Glycomics (CFG) database 
(http://www.functionalglycomics.org). The CFG database contains 31 unique non-
sialylated N-glycan peaks in wild type C57BL/6 mouse brain tissue, 27 (87.1%) of which 
were detected in this experiment. These 27 glycan peaks are marked with a tick on the 
“Previously reported” column in Table 4-1. From the 15 N-glycan peaks that were 
identified in this study but not listed on the CFG data, 5 N-glycan peaks were identical to 
the de-sialylated counterparts of sialylated N-glycans in CFG mouse brain database. 
These 5 N-glycan peaks are marked with a cross on the “Previously reported” column in 
Table 4-1. The remaining 10 N-glycan masses had been previously reported in human 
plasma and serum samples [114], [115], 4 of which had also been detected in mouse 
brain tissue in a study conducted by Hu et al [116] or in whole rat brain tissue in another 
study conducted by Chen et al [117]. These 10 glycan peaks are marked by a plus sign on 
the “Previously reported” column in Table 4-1. This observation further supports that N-
glycans can be directly released and identified from glycoproteins immobilized on slides. 
However, unprotected sialic acid residues have been lost during the acquisition of the 
mass spectra using MALDI [81], [113]. 
Table 4-1. The detected N-glycans from mass spectrometry imaging of mouse brain sections.  
Each glycan in the table is shown by its number of the hexose (Hex or H), N-acetylhexosamine 
(HexNAc or N) and fucose (Fuc or F) residues. Among the 42 detected N-glycans, 27 had been 
reported in the CFG database of wild type mouse brain previously 
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(http://www.functionalglycomics.org).  Of the remaining 15 N-glycans, 5 most likely belong to 
sialylated glycans reported in the CFG mouse brain database that lost their sialic acid residues 
during sample preparation or ionization of the analytes. These 5 glycans are marked by a cross on 
the last column. With the exception of these 5 glycans, all of the remaining 10 detected N-glycans 
had been reported in human plasma and serum samples in earlier studies [114], [115]. Four of 
these 10 remaining glycans had also been reported in other mouse and rat brain tissue [116], 
[117]. 















1 H5N2F0 5 2 0 1257.4231 1257.343 √ Yes 
2 H3N3F1 3 3 1 1282.4548 1282.368 + Yes 
3 H4N3F0 4 3 0 1298.4497 1298.387 + Yes 
4 H3N4F0 3 4 0 1339.4763 1339.417 + Yes 
5 H5N2F1 5 2 1 1403.4810 1403.429 + Yes 
6 H6N2F0 6 2 0 1419.4759 1419.405 √ Yes 
7 H4N3F1 4 3 1 1444.5076 1444.413 + Yes 
8 H5N3F0 5 3 0 1460.5025 1460.401 + Yes 
9 H3N4F1 3 4 1 1485.5342 1485.456 √ Yes 
10 H4N4F0 4 4 0 1501.5291 1501.446 + Yes 
11 H3N5F0 3 5 0 1542.5557 1542.473 + Yes 
12 H7N2F0 7 2 0 1581.5287 1581.446 √ Yes 
13 H5N3F1 5 3 1 1606.5604 1606.455 √ Yes 
14 H4N4F1 4 4 1 1647.5870 1647.482 √ Yes 
15 H5N4F0 5 4 0 1663.5819 1663.476 √ Yes 
16 H3N5F1 3 5 1 1688.6136 1688.508 √ Yes 
17 H8N2F0 8 2 0 1743.5815 1743.498 √ Yes 
18 H6N3F1 6 3 1 1768.6132 1768.494 √ No 
19 H4N4F2 4 4 2 1793.6449 1793.523 √ Yes 
20 H5N4F1 5 4 1 1809.6398 1809.524 √ Yes 
21 H4N5F1 4 5 1 1850.6664 1850.579 √ Yes 
22 H9N2F0 9 2 0 1905.6343 1905.517 √ Yes 
23 H5N4F2 5 4 2 1955.6977 1955.562 √ Yes 
24 H6N4F1 6 4 1 1971.6926 1971.554 √ No 
25 H4N5F2 4 5 2 1996.7243 1996.588 √ Yes 
26 H5N5F1 5 5 1 2012.7192 2012.541 √ Yes 
27 H4N6F1 4 6 1 2053.7458 2053.533 × No 
28 H5N4F3 5 4 3 2101.7556 2101.571 √ No 
29 H6N4F2 6 4 2 2117.7505 2117.567 √ No 
30 H5N5F2 5 5 2 2158.7771 2158.541 √ No 
31 H6N5F1 6 5 1 2174.7720 2174.591 + No 
32 H4N6F2 4 6 2 2199.8037 2199.585 √ No 
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33 H5N6F1 5 6 1 2215.7986 2215.570 × No 
34 H6N6F0 6 6 0 2231.7935 2231.558 + No 
35 H5N5F3 5 5 3 2304.8350 2304.575 √ No 
36 H6N5F2 6 5 2 2320.8299 2320.604 × No 
37 H5N6F2 5 6 2 2361.8565 2361.589 √ No 
38 H6N5F3 6 5 3 2466.8878 2466.621 √ No 
39 H5N6F3 5 6 3 2507.9144 2507.661 √ Yes 
40 H6N6F2 6 6 2 2523.9093 2523.572 × No 
41 H6N5F4 6 5 4 2612.9457 2613.742 √ No 
42 H6N6F3 6 6 3 2669.9672 2670.694 × No 
 
4.4.3    Imaging of N-glycans in different regions of mouse brain sections 
The ion images corresponding to 5 representative fucosylated N-glycans, H4N4F2, 
H5N4F3, H5N5F2, H4N6F2 and H6N5F4 are presented in Figure 4-4B-F. The signal 
intensity for each ion images is obtained by dividing the peak area of each glycan to the 
normalized peak area of the internal glycan standard (DP7) that had been spiked in 
PNGase F digestion solution during printing. In this study we have divided the brain into 
three major regions of brainstem (BS), isocortex (IsoCTX) and hippocampal formation 
(HPF). The AAL lectin histostaining of an adjacent mouse brain section is shown in 
Figure 4-4A. AAL preferentially binds to fucose (α-1,6) or (α-1,3) linked to N-
acetylhexosamine. The AAL staining as well as the ion images indicate that fucosylation 
occurs in all regions of the brain, however, its prevalence seems to depend on the region. 
The AAL staining is strongest in the IsoCTX followed by HPF and generates the weakest 
signal in the BS (Figure 4-4A). Thirty fucosylated N-glycans are identified in this study, 
which comprises more than 70% of total number of glycans. This diversity in the number 
of the fucosylated N-glycans is also observed in their spatial distribution. While some of 
the fucosylated N-glycans such as H4N6F2 (Figure 4-4E) are more abundant in the BS, 
the majority of them show a stronger presence in the IsoCTX and HPF. In summary, the 
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fucosylation increases from the center of the brain towards the cortex. One crucial fact in 
comparing the lectin histostaining data with the MSI images is that the specificity of the 
lectins is far lower than the mass spectrometry. In fact, AAL staining depicts a 
superposition of all the (α-1,6) or (α-1,3) linked fucose-containing N- or O-linked glycans.  
Therefore, even though similar patterns between the two are expected, lectin histostaining 
results are not necessarily reflective of the distribution of single N-glycans over the tissue, 
which explains the differences observed between the lectin staining and MSI results for 
each individual glycan. 
 
Figure 4-4. Ion images of representative fucosylated glycans along with AAL staining of an 
adjacent tissue section.  
(A) Based on the AAL histostaining, fucosylation occurs in all regions of the brain, with a 
relatively higher abundance in the IsoCTX compared to the HPF, while BS has the lowest 
abundance of fucosylation. The ion images correspond to the peaks detected at (B) 1793.523 
(H4N4F2), (C) 2101.571 (H5N4F3), (D) 2158.541 (H5N5F2), (E) 2199.585 (H4N6F2), and (F) 
2613.742 (H6N5F4) Da. The signal intensity in each ion image is calculated by dividing the area 
of the corresponding peak by the normalized peak area of the internal glycan standard. Scale bar, 
2 mm. 
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The ion images corresponding to 5 oligomannose structures of Man5 (H5N2F0), 
Man6 (H6N2F0), Man7 (H7N2F0), Man8 (H8N2F0) and Man9 (H9N2F0) are depicted 
in Figure 4-5B-F. The ConA lectin histostaining of an adjacent section is depicted in 
Figure 4-5A. ConA binds the α-mannose residues attached to the glycans. Therefore, both 
the oligomannose and hybrid N-glycans are potential targets for ConA. The ConA 
staining shows that terminal α-mannose residues are present in all of the aforementioned 
regions, however the signal is stronger in the IsoCTX and BS compared to the HPF 
(Figure 4-5A). The ion images also confirm that oligomannose N-glycans are more 
abundant in the BS. The ConA staining shows a slight asymmetry between the left and 
right half of the brain, particularly in the IsoCTX area. This asymmetry, which could be 
due to the tissue sectioning, was also observed on the ion images of oligomannose N-
glycans. Two additional adjacent tissue sections were similarly analyzed to ensure the 
reproducibility of the results. 
 
Figure 4-5. Ion images of representative oligomannose glycans along with ConA staining of 
an adjacent tissue section.  
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(A) Based on the ConA histostaining, oligomannose structures can be found in all regions of the 
brain. However, they seem to be more abundant in the IsoCTX and BS compared to the HPF. The 
ion images correspond to the peaks detected at (B) 1257.433 (Man5), (C) 1419.486 (Man6), (D) 
1581.539 (Man7), (E) 1743.592 (Man8) and (F) 1905.645 (Man9). The signal intensity in each 
ion image is calculated by dividing the area of the corresponding peak by the normalized peak 
area of the internal glycan standard. Scale bar, 2 mm. 
 
4.4.4    Imaging of N-glycans in glioblastoma tumor implanted in NOD/SCID mouse 
brain 
Analysis of the tumor implanted mouse brain sections confirmed that glycosylation is 
altered during tumorigenesis. Mass spectrometry imaging of these sections revealed 13 
N-glycans with different expressions levels in the tumor compared to the normal brain 
tissue. These N-glycans are listed in Table 4-2. To identify these glycans, two regions of 
interest (ROI) are defined in the brain, such that one ROI surrounds the tumor site and the 
other is mirrored in the normal half of the mouse brain. Two-sample t-test is applied to 
the signal intensities in the ROIs and a p-value threshold of 0.001 is used to determine 
which glycans differ in the tumor. Of the 13 altered N-glycans, 10 are increased in the 
tumor. While there is no obvious glycan structural pattern similarity between the glycans 
with altered abundances, the less abundant glycans are more fucosylated. For instance, 
the majority of the non-fucosylated N-glycans such as oligomannose and non-fucosylated 
complex structures are more abundant in the tumor. Although few fucosylated N-glycans 
are altered in the tumor cells to draw a general conclusion, this observation suggests that 
highly fucosylated glycans carrying antennary fucose residues might be down-regulated 
in tumor cells. Ion images corresponding to some of these glycans are depicted in Figure 
4-6 as examples. The reproducibility of the results was confirmed by imaging an adjacent 
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tissue section using MSI. In this study, we have reported an MSI based technique for 
imaging of N-linked glycans released from immobilized glycoproteins on FFPE sections 
and demonstrated the application of this technique with two examples. We studied the 
spatial distribution of 42 N-glycans on mouse brain coronal sections and also imaged 
distinct N-glycans in patient-derived glioblastoma tumor cells implanted in a mouse brain. 
Similar techniques have been developed for direct profiling of tissue glycans such as on-
surface enzymatic digestion of N-glycans followed by liquid chromatography-mass 
spectrometry [116]. However, this method does not preserve the spatial information 
concerning the distribution of different N-glycans. The developed MSI-based method 
provides a unique tool for high-throughput imaging of N-glycans from FFPE tissue 
sections, which distinguishes it from more conventional histostaining methods. It 
provides unique information regarding the spatial distribution of specific glycan 
structures over the tissue. This information, combined with histology, can provide 
potentially invaluable insight into the histopathology of many diseases. The acquired 
images from the C57BL/6 mouse brain sections suggested that the level of glycosylation 
and the type of N-glycans varies in different brain structures. Fucosylation was 
predominantly observed in the brain, such that more than 70% of all the identified 
glycans appeared to be fucosylated. The most prominent difference in brain N-glycan 
structures was observed between cerebral cortex and brainstem. While oligomannose and 
non-fucosylated complex structures were more abundant in the brainstem, fucosylated N-
glycans showed overall higher signal in the cortex. Our results in the mice brain tumor 
model showed considerable differences between the N-glycosylation in tumor versus 
adjacent normal tissues. Low-abundance N-glycans in the tumor cells had higher levels 
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of fucosylation. On the other hand, high-abundance N-glycans in the tumor cells mostly 
consisted of oligomannose and non-fucosylated complex glycans. Knowing the spatial 
distribution of N-glycans in different brain structures or pathologies can shed light on the 
roles that glycosylation plays in mediating the brain functions. 
Table 4-2. N-glycans and their relative abundance in tumor versus the surrounding normal 
brain tissue.  
Thirteen N-glycans with differential expression in the tumor were identified, most of which were 
more abundant in the tumor cells. N-glycans that are less abundant in tumor have higher levels of 
fucosylation. 





Abundance in tumor 
1 H4N3F0 0 1298.4497 Higher 
2 H6N2F0 0 1419.4759 Higher 
3 H4N3F1 1 1444.5076 Higher 
4 H5N3F0 0 1460.5025 Higher 
5 H7N2F0 0 1581.5287 Higher 
6 H5N4F0 0 1663.5819 Higher 
7 H3N5F1 1 1688.6136 Lower 
8 H8N2F0 0 1743.5815 Higher 
9 H4N4F2 2 1793.6449 Lower 
10 H5N4F1 1 1809.6398 Higher 
11 H9N2F0 0 1905.6343 Higher 
12 H6N4F1 1 1971.6926 Higher 




Figure 4-6. Ion images of tumor N-glycans along with H&E staining of an adjacent tissue 
section.  
(A) Tumor cells are concentrated around the injection site. The ion images correspond to the 
peaks detected at (B) 1905.634 (H9N2F0), (C) 1809.640 (H5N4F1), (D) 1663.582 (H5N4F0), 
and (E) 1996.724 (H4N5F2) Da. The majority of the glycans are more abundant in the tumor; 
however, a few highly fucosylated glycan peaks are more abundant in the surrounding normal 
tissues. Scale bar, 1 mm. 
In addition to FFPE sections, frozen tissue sections can also be analyzed by MALDI 
imaging [118]. For more elaborate results, the current imaging method can be combined 
with quantitative techniques using isotopic labeled standards for high accuracy 
quantitation. For example, by spiking in standard glycans labeled with stable isotope tags, 
one can relatively quantify the images acquired from the tissue sections for targeted 
glycans [65], [119]. In this study, we used the robotic application of the enzyme using the 
microarray printer with 100 μm spot-to-spot spatial resolution and the mass spectral 
images were acquired with spatial resolution of 100 μm. High-density deposition of 
enzyme, high resolution MS acquisition using a faster instrument with higher laser 
repetition rate [120] and imaging in the microscope mode using a triple focus time-of-
flight mass spectrometer [121] could be used to increase the imaging spatial resolution. 
One of the other important limitations of MALDI-MS imaging is the complexity of the 
sample preparation. The dependency of the final results on the changes in the sample 
preparation makes the reproducibility challenging. Incorporation of automatic and semi-
automatic sample handling can improve the reproducibility [122]–[125]. 
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Current tissue analysis is mainly based on histological staining of nuclear and 
cytoplasm using H&E [126], [127], however molecular bases of the structural differences 
between cells can be further differentiated by antibodies to specific proteins using 
immunohistochemistry or nucleic acid probes to DNA or RNA. Immunohistochemistry 
methods are inherently low throughput and subsequently, tissue analysis using these 
methods operate based on single or few molecular probes. On the other hand, mass 
spectrometry provides simultaneous detection and identification of numerous targets, 
which sets it apart as a high-throughput technology. Lectin histostaining has shown that 
various cell types express distinct glycan patterns at different development stages. By 
revealing the glycosylation patterns at single cell level, mass spectrometry imaging of 
glycans can potentially be used to distinguish the cell type and development status based 
on its distinct glycan profile.  
Glycan imaging offers some advantages over protein imaging for detection of disease 
biomarkers. Genetic mutations could result in synthesis of disease-specific aberrant 
glycan structures that are also cell specific. This combination provides a very specific 
target for identification of the underlying pathology, which can be detected using mass 
spectrometry imaging. These glycans are likely to modify different protein sequences, 
many of which contain multiple glycosylation sites. The presence and consequently 
detection of aberrant glycans on multiple glycosites and on various protein sequences 
using mass spectrometry amplifies the effect of the genetic mutation and therefore, 
compared to protein based assays, could potentially improve the detection sensitivity of 
the disease.  
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4.5    Appendix: Tandem mass spectrometry analysis of PNGase-F released 
glycan peaks 
To confirm that the detected mass spectral peaks correspond to glycans, collision-induced 
dissociation tandem mass spectrometry is performed on PNGase-F released peaks on the 
mouse brain tissue sections. For the few glycans, where the precursor signal of the mass 
spectrometry imaging spectrum was too low for tandem mass spectrometry, brain tissue 
extracts are used to extract the brain glycans using the glycoprotein immobilization for 
glycan extraction (GIG) as described previously [26] and the N-glycans are analyzed by 
MALDI-MS for acquiring the MS/MS signal. Briefly, the proteins were extracted by 
sonicating the tissue in RIPA buffer, and were conjugated to AminoLink beads (Thermo 
Fisher Scientific Inc., Rockford, IL) by reductive amination. The glycans were released 
from the immobilized proteins by PNGase F, then purified in carbograph columns and 
finally analyzed by MALDI-MS. The tandem MS spectra that were acquired from the 
mouse brain glycan extracts are marked by an asterisk in Table 4-3. The fragment ions 
are assigned with the help of GlycoWorkbench software. 
 50
Table 4-3. Tandem spectra of PNGase F-released N-glycans.  
Tandem MS spectra are generated for all the detected glycan peaks to confirm their identity. The 
spectra were directly acquired from the tissue section for most of the peaks. In the cases, where 
the precursor peak was too low to generate decent MS/MS signal from the tissue section, mouse 
brain glycan extracts were used instead to acquire tandem MS spectra. These spectra are marked 
by an asterisk. 
  
Precursor m/z 1257.4, glycan H5N2F0 Precursor m/z 1282.5, glycan H3N3F1 
  
Precursor m/z 1298.4, glycan H4N3F0 Precursor m/z 1339.5, glycan H3N4F0 
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Precursor m/z 1403.5, glycan H5N2F1 Precursor m/z 1419.5, glycan H6N2F0 
  
Precursor m/z 1444.5, glycan H4N3F1 Precursor m/z 1460.5, glycan H5N3F0 
  
Precursor m/z 1485.5, glycan H3N4F1 Precursor m/z 1501.5, glycan H4N4F0 
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Precursor m/z 1542.6, glycan H3N5F0 Precursor m/z 1581.5, glycan H7N2F0 
  
Precursor m/z 1606.6, glycan H5N3F1 Precursor m/z 1647.6, glycan H4N4F1 
  
Precursor m/z 1663.6, glycan H5N4F0 Precursor m/z 1688.6, glycan H3N5F1 
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Precursor m/z 1743.6, glycan H8N2F0 *Precursor m/z 1768.6, glycan H6N3F1 
  
Precursor m/z 1793.6, glycan H4N4F2 Precursor m/z 1809.6, glycan H5N4F1 
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Precursor m/z 1850.7, glycan H4N5F1 Precursor m/z 1905.6, glycan H9N2F0 
 
Precursor m/z 1955.7, glycan H5N4F2 *Precursor m/z 1971.7, glycan H6N4F1 
  
Precursor m/z 1996.7, glycan H4N5F2 Precursor m/z 2012.7, glycan H5N5F1 
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*Precursor m/z 2053.7, glycan H4N6F1 *Precursor m/z 2101.8, glycan H5N4F3 
 
 




*Precursor m/z 2174.8, glycan H6N5F1 *Precursor m/z 2199.8, glycan H4N6F2 
  
*Precursor m/z 2215.8, glycan H5N6F1 *Precursor m/z 2231.8, glycan H6N6F0 
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*Precursor m/z 2304.8, glycan H5N5F3 *Precursor m/z 2320.8, glycan H6N5F2 
  
*Precursor m/z 2361.9, glycan H5N6F2 *Precursor m/z 2466.9, glycan H6N5F3 
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Precursor m/z 2507.9, glycan H5N6F3 *Precursor m/z 2523.9, glycan H6N6F2 
  






Chapter 5.    Spectral Library Matching 
for Site-Specific Assignment of Tandem 
Mass Spectra to Intact N-glycopeptides 
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5.1    Summary 
Glycoprotein changes occur in not only protein abundance, but also the occupancy of 
each glycosylation site by different glycoforms during biological or pathological 
processes. Recent advances in mass spectrometry instrumentation and techniques have 
facilitated analysis of intact glycopeptides in complex biological samples by allowing the 
users to generate spectra of intact glycopeptides with glycans attached to each specific 
glycosylation site. However, assigning these spectra, leading to identification of the 
glycopeptides, is challenging. Here, we report a spectral library matching algorithm for 
site-specific identification of intact glycopeptides using higher-energy collisional 
dissociation (HCD) fragmentation of complex samples. In this algorithm, a spectral 
library of glycosite-containing peptides in the sample was built by analyzing the isolated 
glycosite-containing peptides using HCD LC-MS/MS.  Spectra of intact glycopeptides 
were selected by using glycan oxonium ions as signature ions for glycopeptide spectra. 
These oxonium-ion containing spectra were then compared with the spectral library 
generated from glycosite-containing peptides, resulting in assignment of each intact 
glycopeptide tandem MS spectrum to a specific glycosite-containing peptide. The glycan 
occupying each glycosite was determined by matching the mass difference between the 
precursor ion of intact glycopeptide and the glycosite-containing peptide to a glycan 
database. We applied spectral library matching to analyze LC-MS/MS spectra of protein 
extracts from prostate tumor LNCaP cells. Without enrichment of glycopeptides from 
global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing 
tandem MS spectra were assigned to 769 unique intact N-linked glycopeptides, 
representing 344 N-linked glycosites with 57 different N-glycans. The implemented 
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algorithm assigns the HCD LC-MS/MS generated spectra of intact glycopeptides in an 
automated and high throughput manner. Additionally, spectral library matching gives the 
user the possibility of identifying novel or modified glycans on specific glycosites that 
might be missing from the pre-determined glycan databases. 
5.2    Introduction 
Mass spectrometry analysis is routinely used for characterization of glycans and peptides 
in recombinant protein and complex biological samples [63], [107], [128]. Various 
fragmentation techniques have been investigated for analysis of glycopeptides. These 
techniques, mainly operating on the basis of vibrational or electronic excitation energies, 
yield unique fragmentation patterns [85]. For example, collision-induced dissociation 
(CID) results in fragmentation of the attached glycan leaving the peptide backbone intact, 
while electron transfer dissociation (ETD) breaks the peptide backbone leaving the intact 
glycans attached to the amino acids, thus revealing the glycosylation site [74], [88], [89]. 
Therefore, multiple tandem approaches are usually required to fully characterize the 
structure of intact glycopeptides [89]. Higher-energy collisional dissociation (HCD) is 
another fragmentation method that results in fractionation of both glycans and peptides of 
glycopeptides [90]. Eliminating the need for multiple tandem fragmentation approaches, 
HCD fragmentation provides extensive information regarding the peptide backbone of 
each intact glycopeptide, including b and y ions of peptide as well as the mass of glycan 
attached to the glycopeptide [84], [85]. However, assignments of tandem mass spectra to 
intact glycopeptides, including characterization of specific glycosites and their occupying 
glycans, is a challenging but critical step to determine the microheterogeneity of the 
glycosylation at each glycosite [80], [84]–[86], [91], [99], [129]–[131].  
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In this study, we present a novel algorithm for automatic identification of intact 
glycopeptides from HCD spectra of complex biological samples based on spectral library 
matching. This algorithm uses the spectral library built from proteomics analysis of 
glycosite-containing peptides from the complex biological sample using HCD. It takes 
advantage of the fact that tandem mass spectra of intact glycopeptides contain oxonium 
ions and the fragment ions generated through HCD fragmentation of intact glycopeptides 
resemble the pattern of same ions in the tandem MS spectra of their deglycosylated 
counterparts. Therefore, the tandem MS spectra of HCD-fragmented intact glycopeptides 
are selected using oxonium ions and matched against the generated spectral library to 
identify the glycosite-containing peptides and the glycosites. After identification of the 
peptide portion of the intact glycopeptide, the exact precursor mass is used to identify the 
glycan portion by matching with a glycan database. In this study, we analyzed protein 
lysates from LNCaP cells and identified 769 unique intact N-glycopeptides. Besides the 
glycopeptide-matching tandem MS spectra, we identified other tandem MS spectra that 
matched to glycosites in the spectral library, while their corresponding glycan masses 
were not included in the glycan database. Further investigation of the unknown glycans, 
led to assignment of glycans that were modified by an additional moiety with a mass of 
17.018 Da. This modification was particularly shown for high-mannose structures. 
Identifying the peptide portion of the intact glycopeptide first, spectral library matching 
allows for identification of possibly novel glycans as well as modified glycans attached to 
the peptides, which could be of great value particularly in recognizing the pathologically 
induced changes of glycosylation. 
5.3    Methods 
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5.3.1    Sample preparation 
5.3.1.1 Materials and reagents 
LNCaP cell line was obtained from ATCC. Hydrazide beads were purchased from Bio-
Rad laboratories (Hercules, CA). Peptide-N-Glycosidase F (PNGase F) was from New 
England Biolabs (Ipswich, MA). Sequencing-grade trypsin was purchased from Promega 
(Madison, WI). C18 desalting cartridges were purchased from Waters (Milford, MA). All 
other reagents were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise 
specified. 
5.3.1.2 LNCaP sample preparation and mass spectrometry analysis 
LNCaP cells were lysed and the extracted proteins were alkylated by treating with 
iodoacetamide. The sample was digested using trypsin at 37°C overnight. Tryptic 
peptides were labeled with iTRAQ reagents according to the manufacturer instructions, 
then desalted and purified using C18 columns. Ninety percent of the sample was enriched 
for glycosite-containing peptides using the solid phase extraction of glycosite-containing 
peptides (SPEG) method. Briefly, the samples were treated with a 10 mM sodium 
periodate solution and conjugated to hydrazide beads at room temperature in the dark on 
a shaker. Non-specific binding was removed by washing the hydrazide beads. The 
glycosite-containing peptides were detached from the immobilized N-glycans with 
PNGase F treatment and collected for mass spectral analysis. The remaining 10% of the 
tryptic peptide mixture was dried in a speedVac, resuspended in 0.4% acetic acid and 
fractionated for mass spectral analysis. The global tryptic peptides were fractionated 
using basic reverse phase liquid chromatography (bRPLC). The collected 96 fractions 
were combined into 24 fractions. The glycosite-containing peptides that were isolated 
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from the cells using the SPEG technique were directly analysed by LC-MS/MS without 
fractionation. A 1 g of aliquot of each sample was separated through a C18 column on a 
Dionex Ultimate 3000 RSLC nano system (Thermo Scientific) and analysed on a Q 
Exactive mass spectrometer (Thermo Scientific). Data-dependent HCD fragmentation 
was performed on the 15 most abundant ions using an isolation window of 4 m/z. Using 
charge state screening, unassigned, singly, eight and more than eight protonated ions 
were rejected. In addition, an exclusion 25 second window was applied to avoid multiple 
selections of the same ions. 
5.3.2    Data analysis 
5.3.2.1 Building the experimental spectral library (ESL) for glycosite-containing 
peptides 
The mass spectrometry results of the SPEG-enriched glycosite-containing peptides were 
analysed using SEQUEST in the Proteome Discoverer software with the following 
parameters: fixed Cys modification, dynamic PNGase-F facilitated conversion of Asn to 
Asp, and dynamic oxidation of Met in addition to a maximum of two miscleavages. The 
top peptide match for each spectrum was selected. For each peptide, list of singly, doubly 
and triply charged b and y fragment ions were generated. The tandem MS spectra 
matched to each peptide were searched for the presence of these ions. The experimental 
spectral library, which contained the list of target glycosite-containing peptides and their 
present fragment ions, was built based on the results of this search. Any peptide with less 
than 4 observed fragment ions was removed from the target database and the 
experimental spectral library. 
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5.3.2.2 Preprocessing 
The generated raw files containing the acquired mass spectra were converted to mzXML 
files using the msconvert utility in the Trans-Proteomic Pipeline software. The ‘centroid 
all scans’ option was selected. The mzXML file corresponding to each of the tryptic 
global peptide run was opened in MATLAB. The tandem MS spectra of the 
glycopeptides were distinguished from peptide tandem MS based on the presence of 
oxonium ions. These ions belong to glycan free monosaccharides or disaccharides that 
were fragmented during the tandem mass spectrometry analysis. In this step, the tandem 
MS spectra including at least two of the oxonium ions with the masses of 138 (internal 
fragment of HexNAc), 145 (Hex – H2O), 163 (Hex), 168 (HexNAc - 2H2O), 186 
(HexNAc - H2O), 204 (HexNAc), 325 (Hex2), 366 (HexHexNAc), 274 (Neu5Ac - H2O), 
or 292 (Neu5Ac) were isolated as oxonium-ion containing spectra. For the spectra with 
more than 100 peaks, oxonium ions were searched in the top 10% of the mass spectral 
peaks within a 10 ppm window. 
5.3.2.3 Matching the spectra of HCD-fragmented glycopeptides with the ESL 
Each oxonium ion-containing tandem MS spectrum was compared with the compiled 
experimental spectral library (ESL). For each target peptide in the ESL, the percentage of 
the b and y ions that were observed in the tandem MS spectrum was calculated. In 
addition, a list of candidate intact peptide ions was generated for each ESL peptide and 
the tandem MS spectrum was searched for the presence of these ions. A total of 9 intact 
peptide ions were considered including singly, doubly and triply charged intact peptide 
and intact peptide + HexNAc and singly charged intact peptide + HexNAc0,2 cross-ring 
cleavage ion, intact peptide + FucHexNAc and intact peptide + HexNAc2. The peptide 
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matches were first filtered based on the number of their observed intact peptide ions. The 
number of required ions for each peptide depends on the length of the peptide and is 
shown in Table 5-1. The results were further refined by applying an FDR of 1%. A 50 
ppm window was used for matching the b, y and intact peptide ions. 
5.3.2.4 Assignment of glycans attached to glycosite-containing peptides at each 
glycosite 
To identify the monoisotopic peak for each dissociated ion and correct the mass shift, the 
MS spectra were averaged over a window of 15 spectra centered at the precursor MS. 
The first peak in the averaged isotopic cluster corresponding to the precursor mass was 
picked as the monoisotopic peak. The glycan composition was then deduced by first 
calculating its mass from the monoisotopic mass and the peptide mass and then running 
an exact match search against the glycan database with a mass tolerance of 10 ppm. 
5.4    Results 
5.4.1    Building the spectral library for glycosite-containing peptides 
The application of spectral library matching requires an experimental spectral library 
(ESL) of glycosite-containing peptides as a basis to identify the peptide portion of the 
intact glycopeptide in each tandem MS spectrum. The ESL can be generated from the 
glycosite-containing peptides isolated from the sample. The ESL contains the 
experimentally observed b and y ions for each of these peptides, which are the most 
dominant ions in the HCD spectra compared to other ion types. To generate the ESL, the 
glycosite-containing peptides were first isolated from the sample using the solid-phase 
extraction of N-linked glycosite-containing peptides (SPEG) technique [61], [63]. The 
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mass spectral results of the SPEG-enriched glycosite-containing peptides were searched 
using SEQUEST in the Proteome Discoverer (PD) software to identify 2,213 N-linked 
glycosite-containing peptides in the sample and the PD output was used to compile the 
list of peptides in the ESL (Supplementary Table 5-1). The list of b and y fragment ions, 
including doubly and triply charged ions, was generated for the ESL peptides. The 
spectral library was built by identifying all the experimentally observed b and y ions for 
each identified peptide in the sample.  
5.4.2    Matching the spectra of HCD-fragmented glycopeptides with the ESL 
Understanding the pattern of HCD fragmentations of glycopeptides is crucial in 
identifying optimal algorithms for matching of the spectra to glycopeptides. Based on 
observation of HCD fragmented glycopeptide tandem MS spectra, the most abundant 
ions are classified into four main groups of 1) oxonium ions, 2) peptide b and y ions, 3) 
intact peptide attached to partial glycan ions and 4) peptide b and y ions attached to 
partial glycan ions. In the majority of the tandem MS spectra corresponding to 
glycopeptides, a minimum of two oxonium ions are observed among the highest mass 
spectral peaks. We used this characteristic to select glycopeptide tandem MS spectra 
based on the presence of at least 2 signature oxonium ions in the highest 10% of the 
peaks. The second group of ions generated by HCD fragmentation of glycopeptides is the 
peptide b and y ions. These ions, which lie in the mass range between the first and the 
third group, are not as abundant as oxonium ions. However, they have a similar pattern to 
the fragmentation pattern of their deglycosylated glycosite-containing peptide 
counterparts. Figure 5-1A shows the tandem MS spectra of the deglycosylated 
‘YHYN#GTFEDGK’ peptide, while the tandem MS spectrum corresponding to the 
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glycosylated ‘YHYN#GTFEDGK’ is depicted in Figure 5-1B. Comparing the two 
spectra showed that although the overall signal intensity of b and y ions was lower in the 
fragmented glycopeptide, the patterns of these fragment ions were similar between the 
spectra of fragmented intact glycopeptide and the deglycosylated glycosite-containing 
peptide that had been released from glycans using the SPEG technique. In the second step 
of the algorithm, we took advantage of this repeated pattern to identify the peptide 
portion of the intact glycopeptide for each tandem MS spectrum by evaluating its 
matching with the ESL. The overlap between each tandem MS spectrum of intact 
glycopeptide and each peptide entry in the ESL was estimated by calculating the 
percentage of the experimental b and y ions that the two share. The results were later 
refined by removing the matches whose overlap with the ESL did not reach a certain 
threshold. This threshold was determined by the desired false discovery rate (FDR). The 
third group of glycopeptide tandem MS ions of interest, i.e. the intact peptides with 
partial glycan structures were again among the highest peaks in the mass spectra. The 
ions of intact peptides and intact peptides attached to one or two HexNAc residues 
repeatedly were reported among the highest peaks [85], [90]. Therefore, the presence of 
peptide ions with or without partial glycan attachments was used as an additional 
criterion to identify the peptide portion of the glycopeptides. The forth group of ions i.e., 
peptide b and y ions attached to partial glycans can be used to further assign the 
remaining peaks to the glycopeptide ions. It should be noted that the presence of peptide 
b and y fragment ions as well as intact peptides with partial glycan ions depends on the 
length of the peptide, meaning that for longer peptides, b and y ions of peptide backbone 
are more dominantly observed, whereas for shorter peptides, intact peptide ions are more 
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prevalent. Therefore, a combination of all these ions is necessary to ensure the accuracy 
of the matching process. To account for the difference in peptide length, a peptide length-
dependent threshold on the minimum number of present intact peptide ions was used to 
further refine the matches. The threshold was pre-specified for each peptide based on its 
length as shown in Table 5-1. At the end, by subtracting the mass of the identified peptide 
portion from the corrected precursor mass, we calculated the mass of the glycan portion 




Figure 5-1. Comparison of the tandem MS spectra of HCD-fragmented glycosylated 
peptides with and without PNGase F treatment. 
(A) MS/ MS spectrum of the deglycosylated glycosite-containing peptide “YHYN#GTFEDGK” 
is dominated by b and y fragment ions. (B) Tandem MS spectrum of a sample glycosylated 
peptide can be distinguished from the non-glycosylated peptides based on the presence of 
numerous oxonium ions marked by a cross. The intact peptide ions “YHYN#GTFEDGK” with 
partial glycan attachments are usually, and particularly for shorter peptides, the second most 
dominant set of ions in the tandem MS spectrum of a glycosylated peptide. The b and y fragment 




Figure 5-2. Schematic workflow of the spectral library matching approach. 
The glycosite-containing peptides were isolated using the SPEG technique and analyzed with 
HCD LC-MS/MS analysis. The tandem MS spectra were assigned to glycosite-containing 
peptides by proteomics tools, such as PD-SEQUEST, and were used to build the corresponding 
sample-specific ESL by searching the spectra for b and y ions of each identified peptide. The ESL 
was then compared with the mass spectra of intact glycopeptides in the sample to identify the 
peptide portion of the intact glycopeptide corresponding to each oxonium-ion-containing tandem 
MS spectrum. The glycan portion was identified by matching its corresponding mass to the 
glycan database. 
Table 5-1. The minimum number of required intact peptide ions and intact peptide ions 
with partial glycans for each glycosite-containing peptide based on its length. 
The number of observed intact peptide ions decreases for longer peptides. Therefore, a length-
dependent threshold on the number of required intact peptide ions is used to refine the match 
results. 
Peptide Length Minimum number of required 
intact peptide ions 
  5 < Peptide Length < 11 3 
10 < Peptide Length < 16 2 
15 < Peptide Length < 21 1 
       20 < Peptide Length 0 
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5.4.3    Estimation of the false discovery rate using decoy strategy 
False discovery rate (FDR) is a crucial parameter in defining the specificity of the 
identification. The FDR can be calculated through either diversifying the spectra against 
the database of interest or diversifying the peptide database by adding decoy peptides to 
it. For decoy peptides, creating a reverse database is the most common method to 
generate a decoy database, because the reverse database resembles the target peptides in 
terms of number of peptides, peptide length and precursor molecular weight. However, 
the theoretical tandem MS spectra of the reverse database do not match the target 
database. Hence, matches to the reverse database resemble the random matches in the 
target database [132]. The algorithm, matching the ESL to the observed tandem spectra, 
not only used the b and y ions, but also the intact peptide ions with or without attached 
partial monosaccharides to narrow down the peptide-spectral matches (PSM). The 
theoretical tandem MS of the reverse database contains identical intact peptide ions to 
those of the target database, thus elevating the number of random and false matches. In 
this study, to generate the decoy database, we combined the amino acids from all SPEG-
identified glycosite-containing peptides, shuffled them, and broke them into decoy 
peptide sequences with the same length as the target database.  Figure 5-3 shows the mass 
distribution of the target database and an average of 10 randomly-generated decoy 




Figure 5-3. Comparison of the 
distribution of mass/charge (m/z) 
ratio between the target and 
decoy databases.  
The decoy database was generated 
by shuffling the amino acids of the 
peptides in the target database and 
dividing them into peptides with 
the same lengths as the target 
database. The mass/charge ratio 
distribution of the decoy database 
resembles that of the target 
database, which is important for 
evaluating the FDR of the 
algorithm according to the number 
of false matches to the decoy 
database. 
5.4.4    Assignment of glycans attached to glycosite-containing peptides at each 
glycosite 
Correct assessment of the precursor mass is of great significance while assigning the 
glycan portion of the glycopeptide structure corresponding to each tandem MS spectrum. 
The abundance of glycopeptides is considerably lower than that of the peptides in a 
complex sample and the isotopic distribution of glycopeptides is different from that of 
peptides without glycans attached. This results in deviations in the isotopic pattern of 
glycopeptides such as obscuring the monoisotopic peak and subsequently increasing the 
possibility of inaccurate or wrong assignment of monoisotopic peaks of glycopeptides. 
Therefore, the precursor ion mass provided in the mzXML file might be as much as a few 
Daltons off. Using a shifted precursor mass will result in either match failure or matching 
to a wrong glycopeptide structure. For example, the mass difference between two fucose 
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residues and one N-acetylneuraminic acid (Neu5Ac) residue is equal to 1.02 Da. 
Therefore, an error in the detection of the right mass of monoisotopic peak in the 
glycopeptide ion cluster could result in assigning the wrong glycan structure to the 
tandem MS spectrum. 
To determine the accurate mass of the monoisotopic peak of a glycopeptide, we 
calculated the average spectrum of consecutive MS spectra in the vicinity of the 
glycopeptide of interest over the elution time. The averaging improved the cluster 
isotopic pattern and the identification of the monoisotopic peak mass, which 
consequently improved the assignment of the glycopeptide spectrum. Figure 5-4A shows 
a glycopeptide isotopic cluster observed in a single MS1 spectrum and the precursor mass 
reported by the instrument software in the mzXML file. The algorithm identified the 
correct monoisotopic peak after averaging the spectra over a ~1-minute elution time 
window (Figure 5-4B). 
After assignment of precursor mass and the peptide portion of the intact glycopeptide 
and glycosite, the exact mass of the glycan portion was determined by subtracting the 
peptide mass from the glycopeptide mass. To determine the glycan structure on each 
glycosite, the calculated glycan mass was compared with a glycan database and the 
glycan composition was determined at a mass tolerance of 10 ppm. The glycan database 
was composed by compiling several human serum or plasma N-glycan libraries [114], 
[115] with N-glycans identified from various human samples analyzed in our lab [26], 
[65]. All glycans with equal number of Hex, HexNAc, Fuc, and Neu5Ac monosaccharide 
residues in their compositions were grouped together and represented as a single entry, 
leading to 208 unique N-glycan compositions in the database (Supplementary Table 5-2). 
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Figure 5-4. Detection of the glycopeptide monoisotopic peak.  
(A) Isotopic pattern of a glycopeptide peak (TN#ITLVCKPGDLESAPVLR, Man9). The reported 
precursor mass is 2 Da off the monoisotopic peak. (B) Precursor mass correction by averaging a 
window of MS spectra over the glycopeptide elution time greatly improves the isotopic 
distribution of the cluster by comparison with the theoretical pattern, thus improving the detection 
of monoisotopic mass. The precursor peak and the monoisotopic peak are marked by a red arrow. 
5.4.5    Glycoproteomics analysis of the LNCaP cells using spectral library matching 
To identify glycopeptides from a complex sample, twenty-four fractions of LNCaP 
tryptic peptides and SPEG-enriched glycosite-containing peptides were analyzed, and 
glycopeptides were identified using the spectral library matching algorithm. The 
generated ESL for the LNCaP samples, which was built based on the mass spectrometric 
analysis of SPEG-enriched glycosite-containing peptides, contained 2,213 target peptides 
(Supplementary Table 5-1). Of the total number of 985,509 spectra in all 24 fractions, 
7,243 contained at least 2 oxonium ions and were isolated as tandem spectra 
corresponding to glycopeptides.  
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With no filtering on the percentage of observed b and y ions, a total of 137,227 PSMs 
were attained, where each matched tandem MS scan was matched to an average of 23.9 
PSMs. Refining the results based on a threshold on the minimum percentage of overlap 
between the ESL and the spectra to achieve a reasonable FDR, as expected, decreased the 
number of PSMs.  
For estimation of the FDR, the decoy database was built as described and merged 
with the target database resulting in a total of 4,426 peptides in the peptide database. The 
FDR was calculated based on the percentage of PSMs matched to the decoy database. A 
curve was calculated by changing the threshold on the percentage of b and y ion overlap 
with ESL and calculating and plotting the FDR as a function of this threshold. The 
optimal threshold for refining the results was determined by the desired FDR on this 
curve. Figure 5-5 shows the FDR as a function of this threshold in red and black, where 
the red curve corresponds to spectral library matching and the black curve corresponds to 
similar analysis, with the only difference that the match refinement step based on the 
number of observed intact peptide ions was omitted. From this figure, we estimated that a 
threshold of 40% results in an FDR of approximately 1%. In addition, this figure 
demonstrated how the use of intact peptide ions for filtering the results improved the 
FDR. Using a 1% FDR cut down the number of PSMs to 4,213 and the average number 
of PSMs per matched tandem MS scan to 1.6. 
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Figure 5-5. Estimation of FDR for glycoproteomics analysis of the LNCaP samples. 
The FDR was calculated as a function of the percentage of b and y ions in the tandem MS spectra 
matching the ESL library in the LNCaP cell analysis. The red curve, showing the FDR analysis 
for the spectral library matching algorithm, shows that an FDR of 1% is achieved by setting this 
threshold at 40%. The FDR curve in black shows the results of FDR calculation omitting the use 
of intact peptide ions for refining the results. Comparing the two curves shows that taking the 
intact peptide ions into account improves the FDR and, subsequently, the specificity of the 
algorithm. 
Applying the aforementioned filters in this study, 344 unique glycosite-containing 
peptides were matched to 57 N-glycan compositions and 769 unique intact N-
glycopeptides were identified from LNCaP cells using the spectral library matching 
algorithm (Supplementary Table 5-3).  
In addition to performing global analysis, using this tool, we can look at the 
heterogeneity of any glycosite of interest or the glycosylation heterogeneity profile of a 
sample. Figure 5-6 shows the distribution of different N-glycan compositions in the 
LNCaP sample, where each bar shows the number of PSMs that matched to a specific N-
linked glycan in the sample. According to the glycan profile of LNCaP cells, they 
contained high-mannose, fucosylated only, sialylated only, fucosylated and sialylated, 
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and other glycans without fucose and sialic acid in hybrid or complex structures; 
however, the high-mannose structures were more prevalent. The lower abundance of 
sialylated glycans could be attributed to instability of sialic acid residues and their loss 
during sample preparation [65], [81], [113].  
 
Figure 5-6. Glycan profile of the LNCaP cells. 
The number of PSMs pertaining to each glycan is accumulated over all the glycosites. The 
LNCaP cells contain high-mannose, fucosylated, and sialylated glycans among other N-glycan 
structures. The high-mannose structures are the most abundant ones identified in the sample, 
followed by fucosylated glycans. Sialylated glycans are the least abundant structures. Addition- 
ally, nonfucosylated, nonsialylated hybrid, and complex N-glycans, marked as others on this 
figure, were observed in LNCaP cells.  
5.4.6    Analysis of unmatched glycan masses in LNCaP samples 
Spectral library matching assigns the peptide portion of the intact glycopeptide to the 
oxonium ion-containing tandem MS spectra, while the decoy strategy ensures the 
accuracy of the peptide match. The glycan portion is determined by calculating the 
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glycan mass and matching it to the glycan database. Therefore, if the corresponding 
glycan structure is missing from the glycan database (Supplementary Table 5-2), the 
glycan portion of the glycopeptide remains unspecified. This attribute could potentially 
lead into discovery of novel glycans or glycan modification. In this analysis, we observed 
examples of LNCaP glycopeptide tandem MS spectra where the peptide portion of the 
glycopeptides were assigned to glycosite-containing peptides in the ESL, while the 
calculated glycan masses were missing from the glycan database. As an example, a 
minimum of 20 spectra in the glycoproteomics analysis of LNCaP cells resulted in a 
glycan [M+H]+ mass in a 10 ppm window around 1414.512 Da matching to 15 different 
glycosites; however, the glycan database match did not result in identification of the 
glycan portion of the intact glycopeptide. In addition, searching the UniCarbKB [133] 
database for this glycan using the Glycomod tool [134] retrieved no matches. To further 
analyze the unassigned glycan structure, we re-investigated the tandem MS spectra of 
LNCaP glycans that had been isolated from the sample and analyzed by HCD LC-
MS/MS. Figure 5-7 depicts the tandem MS spectrum of the glycan corresponding to 
[M+2H]2+ mass of 707.76 Da, equivalent to [M+H]+ mass of 1414.512 Da generated 
through ESI LC-MS/MS analysis of isolated LNCaP glycans on a Q Exactive instrument. 
The assignment of fragment ions, generated by the Glycoworkbench software [112], to 
numerous fragmented high-mannose ions suggested that the corresponding unknown 
glycan was a modified high-mannose structure. In fact, the mass of this glycan is within 
10 ppm of a Man6 glycan modified by a moiety with molecular weight of 17.018. This 
observation, i.e. addition of moiety with a mass of 17.018 Da to a glycan, was observed 
for Man5, Man7, Man8 and Man9 as well. While an estimated of 700 PSMs matched 
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unmodified high-mannose structures collectively, about 50 PSMs appeared to match 
modified high mannose glycans suggesting that around 7% of these structures were 
modified by an additional 17.018 Da moiety. 
 
Figure 5-7. Assignment of modified glycans.  
Tandem MS spectrum of an uncharacterized glycan peak at [M + H]+ of 1414.512 is assigned to 
glycan fragment ions. Presence of several oxonium ions in the spectrum of the unknown structure 
ensures that it belongs to a glycan. Also, assignment of numerous peaks to fragments of Man5 
and Man6 glycans suggests that the unknown glycan might be a modified high- mannose 
structure. Even though the tandem MS spectrum of this glycan is not sufficient to accurately 
determine the structure, the mass of this structure equals that of Man6 modified by a moiety with 
a mass of 17.018 Da.  
5.5    Discussion and conclusion 
Assignment of intact glycopeptides to tandem MS spectra of simple and complex 
biological samples is a challenging task and several studies have attempted to tackle this 
challenge. Segu et al showed that HCD fragmentation of intact glycopeptides resulted in 
distinct peptide + GlcNAc ions [85]. Based on this observation, Mayampurath et al 



























developed GlypID 2.0, a tool for assignment of glycopeptide to fragmented glycopeptides 
[91]. Nwosu et al used a combination of accurate precursor mass and the CID-generated 
fragment ions in tandem MS spectra for assignment of the intact glycopeptides [80]. 
Singh et al took the HCD product ion-triggered ETD of glycopeptide ions and analyzed 
the ETD fragmented tandem MS spectra using common proteomics tools by introducing 
the known glycans in the sample as variable modifications [86]. Parker et al used 
proteomics and glycomics techniques to first build databases of possible glycans and 
glycopeptides in the sample and identified the intact glycopeptides by matching their 
accurate precursor mass to their concatenated glycopeptide database [129]. He et al 
developed a software tool called GlycoMaster DB for assignment of glycopeptides to 
HCD/ETD or HCD spectra [99]. These algorithms for glycopeptide assignments assign 
the tandem spectra based on accurate mass of the precursor ion to potential glycopeptides, 
which rely on the prior identification of both peptides and glycans in the databases.  
Spectral matching of HCD fragmented intact glycopeptides to a tandem mass spectral 
library of glycosite-containing peptides in a complex sample can be used to reliably 
identify the peptide portion of these glycopeptides, yielding a false discovery rate in the 
order of 1%. Knowing the peptide portion, the mass of the glycan portion can be 
calculated by subtracting the peptide mass from the mass of the precursor ion. Therefore, 
the glycan structure can be characterized by comparing the glycan mass with the glycan 
database. Due to various factors, the search for glycan structure might not result in a 
match. Examples include novelty of the glycan, uncharacterized or sample preparation-
induced glycan modifications or errors associated with calculation of the glycan mass. By 
highlighting these spectra, spectral library matching provides the user with a chance to 
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further investigate those spectra, where despite reliable peptide identification, the glycan 
structure remains ambiguous. Using this strategy, our data showed the possibility of a 
novel modification on glycans with a mass of 17.018 Da. Consideration of this 
modification could lead to identification of more glycans and intact glycopeptides in 
biological samples. Similar approaches can be used to identify more uncharacterized 
glycan modifications. 
One of the advantages of spectral library matching is that the accumulation of verified 
glycopeptide-spectral matches over time facilitates the assignment of newly generated 
spectra. Furthermore, this concept can be used to group the spectra corresponding to 
different forms of a peptide to generate a universal fingerprint for that peptide. 
Comparison of tandem MS spectra to specific universal fingerprints can be facilitated by 
the many advanced pattern recognition methods developed in the field of signal 
processing and can result in quick, efficient, and targeted identification of different forms 
of post-translationally modified peptides in large mass spectrometry datasets.  
The human glycoproteome carries the information of not only glycans and proteins, 
but also glycosylation sites along with the array of glycans present at each site. Our 
understanding of the glycoproteome is limited, partly due to shortage of the tools 
available for exploring the glycoproteome. Expanding the glycoproteomics toolkit would 
provide an opportunity for studying the glycoproteome of specific cells and tissues and 
revealing changes induced by certain pathologies at molecular level. This knowledge is 







Chapter 6.    Software-Assisted N- and 




6.1    Summary 
Glycoproteomics, the high-throughput study of protein glycosylation using mass 
spectrometry, is a rapidly growing field. Recent advances in instrumentation have 
facilitated the analysis of intact glycopeptides, which is essential for preserving the 
information of glycosylation microheterogeneity in samples. While massive amount of 
data is being generated at a rate of ~1 gigabytes/hour on a single instrument, with the 
software and analytical tools lagging behind, this data is not being fully interrogated. 
Therefore, there is a great need for analytical tools that can dig the glycoproteomics data. 
Here we report a software tool for identification of intact N- and O-glycopeptides from 
simple and complex biological samples, such as recombinant glycoprotein cocktails and 
cell, serum or tissue samples. GPQuest provides two algorithms named “Precursor Mass 
Matching” and “Spectral Library Matching” for assignment of glycopeptides to 
spectra, which offer the advantages of lower simulation time and more identifications, 
respectively. In addition, it uses machine learning to predict the glycosylation type (N- or 
O-) for each spectrum based on its spectral features with > 90% accuracy. The interface 
provides the user with the freedom to narrow down the glycopeptide-spectral matches 
based on oxonium ions, matching b and y ions, and intact peptide ions with partial 
glycans. Moreover, GPQuest calculates scores for each glycopeptide-spectral match 
according to the number of matching fragment ions and the intensity coverage of the 
spectrum by these ions. A decoy strategy was incorporated in GPQuest to validate the 
results by providing statistics on the false discovery rate. Finally, GPQuest was used for 
identification of potentially novel O-linked glycosylation sites on bovine fetuin. 
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6.2    Introduction 
Much of the efforts in the glycoproteomics field have focused on N-glycosylation [2], 
[43], [91], [97]–[99] and little has been done to differentiate between N- and O-
glycosylation in the assignment of the tandem MS spectra. Higher-energy collisional 
dissociation (HCD) alone or in combination with other fragmentation methods has 
proven to be effective in fragmentation and identification of N-glycoproteins [2], [43], 
[84], [86], [90]. However, the use of HCD for inspection of O-glycoproteins remains 
unexplored. The spectra of HCD fragmented O-glycopeptides contain valuable 
information that require proper analytical tools for interpretation. Assignment of O-
glycopeptide structures has been historically more challenging than N-glycopeptides for 
several reasons. First, lack of a universal enzyme for releasing the O-glycans from their 
host proteins requires the use of chemical methods such as beta-elimination, which 
results in suboptimal removal of O-glycans. Second, unlike N-glycosylation sites that are 
scattered sporadically throughout the protein backbone, O-glycosylation sites tend to be 
located in close proximities in S/T rich sequences [135]. O-GalNAc type glycoproteins 
include Serine and Threonine rich short sequences that are heavily O-glycosylated. The 
proximity of these sites makes it difficult to distinguish the exact structure and site of 
each O-glycan on the peptide backbone. Last, unlike N-glycosylation where the 
modification happens on a handful of known motives (NXS, NXT, and less commonly 
NXC and NXV [32]) O-glycosylation does not target a specific motif, meaning that it can 
happen on any of the S, T or even Y residues. 
Several strategies have been employed for enrichment of glycopeptides. Oxidation of 
glycans and immobilizing them on solid support has been proven effective for extraction 
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of glycopeptides [63], [94]. In case of sialylated O-glycoproteins, sialic acids can be 
selectively oxidized under mild periodate oxidation conditions and O-glycopeptides can 
be eluted by acid hydrolysis of the sialic acid glycosidic bonds [94]. Clearly, the 
sialylation information of the sample cannot be retrieved using this strategy. Sialylated 
glycoproteins are shown to bind to titanium dioxide beads at low-pH. Combining this 
characteristics with HILIC enrichment, Palmisano et al have successfully isolated 
formerly sialylated glycopeptides from protein mixtures [69]. Lectin weak affinity 
chromatography (LWAC) is another technique for isolation of O-glycosylated peptides 
by incorporating different lectins such as wheat germ agglutinin (WGA) [136] and 
Jacalin [137], [138]. Heterogeneity of O-glycans contributes to the complexity of O-
glycoproteome enrichment. To tackle this challenge, a common strategy for isolation of 
O-linked glycopeptides is engineering the cells to produce simple homogenous O-glycan 
structures. This is accomplished by targeting the O-glycosylation elongation genes by 
zinc-finger nuclease, thus creating ‘SimpleCell’ lines that only express trimmed O-
glycans [83], [139]. This technique is valuable in locating the glycosylation sites, 
however, the O-glycan structures are lost during the process. Once the glycopeptides are 
collected, they are separated and analyzed by LC-MS/MS and the results are interpreted 
using glycoproteomics software tools. 
Here we report the development of GPQuest, a software tool for analyzing higher-
energy collisional dissociation (HCD) fragmented spectra of both N- and O-linked 
glycopeptides. GPQuest offers two algorithms for matching the tandem mass spectra to 
intact glycopeptides: precursor mass matching and spectral library matching. This tool 
supports sample preparation modifications such as stable isotope labeling by amino acids 
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in cell culture (SILAC) and isobaric tags for relative and absolute quantification (iTRAQ). 
For ensuring the specificity of the matches, GPQuest uses a decoy strategy to estimate the 
false discovery rate (FDR) for the analysis [2]. In this strategy, a decoy database is built 
by concatenating and shuffling the amino acids of the target database and dividing the 
generated sequence into decoy peptides. The users can choose from three scoring 
schemes including: fragment ion count score, Morpheus score and intensity score (Table 
6-1). A unique feature of GPQuest is its ability to distinguish the tandem mass spectra 
corresponding to N- and O-linked glycopeptides based on the intensity of oxonium ions. 
In this strategy, binary classification using logistic regression is used to determine the 
glycosylation type based on the intensities of 10 oxonium ions resulting from detachment 
and internal fragmentation of hexose, N-acetylhexosamine, and sialic acid residues from 
glycans. In this study, we have demonstrated the application of GPQuest for 
identification of potentially novel O-glycosylation sites on bovine fetuin. 
6.3    Methods 
6.3.1    GPQuest software development 
GPQuest is a software package developed in MATLAB (R2014b) for glycoproteomics 
analysis of mass spectrometry data [2]. Standalone version of GPQuest, is available for 
Mac and Windows 64-bit operating systems and can be downloaded at 
http://www.biomarkercenter.org/GPQuest. The graphical user interface (GUI) of 
GPQuest is shown in Figure 6-1. The users can choose between two algorithms 
(precursor mass matching and spectral library matching) for assignment of intact 
glycopeptides to tandem mass spectra. SILAC and iTRAQ labeling are supported in 
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GPQuest. Users can extract the intensities of ions (iTRAQ or custom reporter ions) of 
interest for quantification purposes. The software is designed to accept mzXML2.0 files 
as input data files and excel or comma-separated value files as glycan and peptide 
databases. Sample N- and O-linked glycan databases are incorporated in the examples 
included in the package. In glycoproteomics analysis, one of the first steps is to determine 
whether a tandem MS spectrum belongs to glycopeptides. This is accomplished by 
checking the presence of glycan oxonium ions, which are low-mass ions corresponding to 
mono or disaccharides broken away from the glycan portion of the glycopeptides. The 
intensities or number of these ions might be affected by fragmentation energy and mass 
analysis parameters. Therefore, GPQuest gives the user the freedom to determine the 
filters required to select a spectrum as pertaining to glycopeptides by determining the 
required minimum number and intensities of the oxonium ions. Furthermore, depending 
on the type of analysis, the specificity and the glycosylation type, the spectral features 
vary. Therefore, users can choose what type and charge states of fragment ions are to be 
considered in their analysis and how many intact peptide ions are expected depending on 
the length of the glycopeptide of interest. Also, depending on the user’s preference three 
scoring formula for glycopeptide-spectral matches (GPSM) are provided. The fragment 
ion count scoring takes into account the number of matching peptide fragment ions for 
each glycopeptide. The Morpheus score focuses on the number of matching fragment and 
intact peptide ions with a glance at the intensity coverage of the spectra by these ions. 
The intensity score mainly relies on the intensity coverage of the spectra by the matched 
ions but also takes the number of these matching ions into account as a secondary 
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criterion. Last, users can choose the confidence level of analysis by selecting the desired 
false discovery rate threshold. 
 
Figure 6-1. Graphical user interface of GPQuest. 
The GUI comprises of the following panels: a) algorithms, b) sample preparation, c) reporter ion 
extraction, d) analysis setup, e) precursor mass matching, f) spectral library matching, g) selection 
of oxonium ion containing spectra, h) fragment and intact peptide ions and i) filtering. 
6.3.1.1 Precursor mass matching and spectral library matching 
Precursor mass matching is the assignment of the tandem MS spectra to their 
corresponding structures by comparing the precursor mass with a glycopeptide database. 
After the initial matching of the precursor mass, fragment ions are used to score the 
glycopeptide-spectral matches and refine the search results (Figure 6-2A). In spectral 
library matching on the other hand, the corresponding peptide to a spectrum can be 
identified by comparing that spectrum with a spectral library of peptides of interest 
(Figure 6-2B). Each of these methods offers unique advantages and if used properly can 
advance high-throughput analysis of mass spectrometry data. For example, precursor 
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mass matching is the faster of the two algorithms. On the other hand, it is limited to 
known peptides and glycan structures included in the database. Furthermore, addition of 
each glycan structure or other post-translational modification (PTM) increases the search 
space for precursor mass matching analysis. Therefore, this technique is not easily 
scalable to analysis of multiple PTMs. Precursor mass matching is ideal when a quick 
solution is desirable and limited number of peptide modifications is under investigation. 
Spectral library matching is discussed in detail in chapter 5. 
 
Figure 6-2. Precursor mass matching and spectral library matching for glycopeptide 
identification. 
A) In precursor mass matching a database of potential glycans and glycosite-containing peptides 
in the sample is used to build a database of theoretical glycopeptides in the sample. Comparing 
the mass of precursor ion for each tandem MS spectrum generates a list of the most likely 
corresponding glycopeptides. B) In spectral library matching the tandem MS spectrum is 
compared with a spectral library of the glycosite-containing peptides in the sample. The closest 
spectral match pinpoints the most likely peptide corresponding to the spectrum. Knowing the 
glycopeptide precursor mass and the peptide mass, the glycan mass can be calculated and its 
structure identified by searching a glycan database. 
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6.3.1.2 Scoring of glycopeptide-spectral matching 
Three scoring schemes are implemented in GPQuest and users can, depending on their 
analysis and quality of data, choose the scoring system that best fits their needs. These 
scoring systems are named: 1) Fragment ion count score, intensity score and Morpheus 
score (Table 6-1). Each scoring method has unique pros and cons as discussed below. 
 
Table 6-1. GPSM score definitions 
Score Definition 
Fragment ion count No. of fragment peptide b and y ions in the spectrum 
Morpheus No. of fragment peptide b and y ions + No. of intact peptide ions 
+ Intensity fraction of matching b, y and intact peptide ions 
Intensity Intensity % of b, y and intact peptide ions + No. of b, y and intact 
peptide ions 
Fragment ion count score is calculated for each GPSM by counting the number of 
peptide fragment b and y ions that is detected in the tandem MS spectrum. Morpheus 
score is a modification of the score reported by Wenger et al for peptide-spectral matches 
in high mass resolution proteomics analysis [140]. The original Morpheus score is the 
sum of the number of fragment b and y ions and the intensity fraction of the tandem MS 
spectrum covered by the matching fragment ions. For glycoproteomics analysis, we have 
modified the score in two ways. First, in addition to the fragment b and y ions, this score 
includes the number of intact peptide ions such as peptide+ or peptide-HexNAc+, which 
are major peaks in HCD fragmented spectra of glycopeptides. Second, the fractional part 
of the score is the intensity fraction of b, y and intact peptide ions after removing the 
oxonium ions from the spectra. Excluding the oxonium ion intensities ensures that these 
ions, which are disproportionally abundant in the spectra of N-glycopeptides, do not 
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interfere with the scoring of the GPSMs. Intensity score, on the other hand, is designed to 
emphasize the spectrum intensity coverage by the matching ions as opposed to their 
number. In particular, this scoring devalues the GPSMs that correspond to randomly 
matched ions to noisy spectra. Here, the score is calculated by adding the number of b, y 
and intact peptide ions to the percentage (as opposed to fraction) of the intensity of the 
tandem MS spectrum covered by the matching ions. 
6.3.2    Sample preparation and mass spectrometry analysis 
6.3.2.1 Materials and reagents 
Sequencing-grade trypsin was purchased from Promega (Madison, WI). C18 desalting 
cartridges were purchased from Waters (Milford, MA). Glycophorin A (P02724), bovine 
fetuin (Q58D62 and P12763) and ovalbumin (P01012) were purchased from Sigma 
Aldrich. All other reagents were purchased from Sigma Aldrich (St. Louis, MO) unless 
otherwise specified.  
6.3.2.2 Glycoprotein sample preparation 
The glycoproteins of interest, glycophorin A, ovalbumin and fetuin, were first denatured 
using 8 M urea in 1 M ammonium bicarbonate buffer with 10 mM tris(2-
carboxyethyl)phosphine (TCEP) for 1 hour at room temperature. Denaturing was 
followed by alkylation using iodoacetamide for 30 min at room temperature in the dark. 
The alkylated glycoproteins were then digested using high-grade trypsin in a 200 mM 
ammonium bicarbonate buffer and incubated at 37 °C overnight. The peptides were 
purified using C18 columns.  
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6.3.2.3 Liquid chromatography and mass spectrometry analysis 
For each glycoprotein, a 0.4 μg aliquot was separated through a C18 column on a Dionex 
Ultimate 3000 RSLC system and analysed on a Q Exactive mass spectrometer (Thermo 
Scientific). Data-dependent HCD fragmentation was performed on the 10 most abundant 
ions using an isolation window of 2 m/z and fixed first mass of 100 m/z.  Unassigned, one, 
eight and more than eight protonated ions were rejected. 
6.3.3    Data analysis 
The mass spectrometry raw files were converted to mzXML files using the Trans-
Proteomic Pipeline (TPP), with the “centroid all scans” option selected. The precursor 
mass matching algorithm on GPQuest was used to analyse the mzXML files. 
For the fetuin, ovalbumin and glycophorin A samples, the following parameters were 
used in GPQuest: Mass tolerance was set to 10 and 20 ppm at MS1 and MS2 levels, 
respectively. N- and O-linked glycosylation analysis were conducted simultaneously. In 
silico tryptic digestion of the amino acid sequences of these three glycoproteins with 
UniProt IDs of Q58D62, P12763 (fetuin), P02724 (glycophorin A) and P01012 
(ovalbumin) was used to generate the peptide database for this analysis. Up to two missed 
cleavages and maximum two variable oxidations of Methionine were allowed. A tandem 
MS spectrum was marked as oxonium-ion containing for further glycoproteomics 
analysis if it contained a minimum of 2 oxonium ions in the 5% highest peaks, with the 
ion at 204 being mandatory as one of the two. The bottom 10% of the peaks were 
removed as low-quality peaks and singly charged b and y peptide fragment ions were 
included for scoring of the GPSMs. For peptides shorter than 11 amino acids, presence of 
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the intact peptide ion was mandatory. The FDR was set to 1%. For comparison of the 
three scoring formulas, the presence of intact peptide ion was not mandatory. 
6.4    Results 
6.4.1    Classification of tandem mass spectra based on glycosylation type 
The tandem MS spectra of glycopeptides carry valuable information about the structure 
that they represent. During HCD fragmentation of glycopeptides, various groups of ions 
are generated. A key signature of glycopeptide spectra is the presence of oxonium ions 
that correspond to detached mono- or disaccharides cleaved off the glycans. These 
oxonium ions not only help distinguish the glycosylated from non-glycosylated peptides, 
but also could shed light on the structure of their glycan of origin. We have observed that 
in particular, the oxonium ions released from N- and O-linked glycopeptides were quite 
different in their intensities and distribution. Figure 6-3 shows the tandem MS spectra of 
two glycosylated peptides. The top panel shows the spectrum of the peptide 
‘VTCTLFQTQPVIPQPQPDGAEAEAPSAVPDAAGPTPSAAGPPVASVVVGPSVVA
VPLPLHR’ which is part of the bovine fetuin sequence and has known O-glycosylation 
sites. The spectrum shows this peptide modified by an O-linked glycan structure with 
N3H3F0S1 composition, where N, H, F and S represent the number of HexNAc, Hexose, 
Fucose and Neu5Ac residues, respectively. The bottom panel depicts the N-glycopeptide 
‘LCPDCPLLAPLNDSR’ that has been modified by N-linked N4H5F0S1. This peptide 
too belongs to bovine fetuin and has a known N-glycosylation site. Both glycans are 
sialylated non-fucosylated forms, consist of 7 and 10 monosaccharides respectively, and 
are of comparable size.  The figure also shows the mass/charge range spanning the 
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oxonium ions and their intensities. Seven ions are annotated on this figure including 138, 
168, 186 and 204 (HexNAc ions), 274 and 292 (Neu5Ac ions) and 366 (Hex-HexNAc 
ion).  There are a few notable distinctions between the two spectra. For example, the 
ratios of the HexNAc ions intensities are significantly different between spectra of N- and 
O-linked glycopeptides. The Neu5Ac ions have a higher share of the total intensity in the 
O-linked spectrum compared to the N-linked spectrum, while the opposite is true for the 
Hex-HexNAc ions. 
 
Figure 6-3. Intensity of glycan oxonium ions differs between HCD fragmented O- and N-
linked glycopeptides. 
The tandem MS spectrum of HCD fragmented glycopeptides with (A) O-linked and (D) N-linked 
glycans are shown. Focusing on the lower mass range that covers the oxonium ion range for (B) 
O-linked and (E) N-linked glycans shows that these two glycosylation types create very different 
patterns of fragment ions in this range, even though the corresponding glycan structures 
N3H3F0S1 (C) and N4H5F0S1 (F) are of comparable size. There are several differences in the 
intensities of the oxonium ion between these two glycopeptides. Among these differences are the 
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intensity ratios of HexNAc related oxonium ions at 138, 168, 186 and 204, the intensities of 
Neu5Ac related oxonium ions at 274 and 292 and the intensity of HexNAc-Hex oxonium ion at 
366. 
 
In order to systematically study the difference between spectral features of N- and O-
linked glycopeptides, a training dataset was generated of the HCD fragmented spectra of 
different glycopeptides. This dataset was built by first analyzing the glycoproteomic data 
of ovalbumin, glycophorin A and fetuin using GPQuest. Ovalbumin was selected for this 
experiment because it is an N-glycoprotein, with no reported O-glycosylation sites and 
therefore provided a number of N-linked glycopeptide spectra for the training dataset. 
Glycophorin A, on the other hand, is heavily O-glycosylated and therefore provided 
many O-linked glycopeptide spectra. The fetuin glycoprotein, purchased from Sigma 
Aldrich, consists of two homologues of fetuin-A and fetuin-B with UniProt IDs of 
P12763 and Q58D62, both containing reported N- and O-glycosylation sites. Ideally, the 
training dataset should be diversified to cover a wide variety of possible cases.  The size 
and diversity balance of the O-linked and N-linked entries in the database were improved 
by adding 79 manually verified O-linked glycopeptide spectra from our study of gp120 
glycosylation [90] to this dataset. Several additional filters were applied to GPQuest 
output to ensure that the spectra selected for the training dataset were of high quality with 
confident glycopeptide assignments. First of all, only GPSMs including peptides with 
known glycosylation sites were selected. Also, GPSMs with intensity coverage below 
10% and total spectrum intensity below 5x105 were excluded from the dataset. For 
spectra of O-linked glycopeptides, only GPSMs assigned to peptides lacking any N-
glycosylation sites were considered. Concatenation of the data from ovalbumin, 
glycophorin A, fetuin and gp120 resulted in a training dataset containing 872 and 527 
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HCD fragmented spectra of N- and O-linked glycopeptide, respectively.  FDR was set to 
1% for this analysis. 
 
Figure 6-4. Spectral differences between O- and N-linked glycopeptides in the oxonium ion 
region can be used to predict the glycosylation type for each glycopeptide spectrum. 
The intensities of nine different oxonium ions normalized by the intensity of HexNAc ion at 204 
are depicted. The plotted ions are as follows: (A) Hex-related ion at 145, (B) Hex ion at 163, (C) 
Hex-Hex ion at 325, (D) HexNAc-related ion at 138, (E) HexNAc-related ion at 168, (F) 
HexNAc-related ion at 186, (G) Hex-HexNAc ion at 366, (H) Neu5Ac-related ion at 274 and (I) 
Neu5Ac ion at 292.  Clearly, there are differences between the two types of glycosylation in 
terms of their oxonium ion intensities. These differences are more pronounced for some of these 
ions. In particular, normalized intensity of 186 is significantly higher in O-linked spectra. The 
other two HexNAc related ions are however higher in the N-linked spectra. Furthermore, sialic 
acid residues have a greater share in the oxonium ion intensities of O-linked spectra while Hex-
related oxonium ions are generally higher in the N-linked spectra. These differences, fed into a 
machine learning algorithm, can help predict the glycosylation type and classify the spectra. 
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Figure 6-4 illustrates the intensities of oxonium ions in N- and O-linked glycopeptide 
tandem MS spectra side by side. The intensities were extracted for nine oxonium ions and 
normalized by the intensity of the tenth ion at m/z 204, which is the intact HexNAc 
oxonium ion and observed in almost all the spectra that belong to glycopeptides. The 
distribution of the oxonium ions are plotted for N-linked (in red) and O-linked (in blue) 
spectra. As shown, there are significant differences between the two types of 
glycosylation: 1) The Hex related oxonium ions (145, 163 and 325) are usually more 
abundant in spectra of N-linked glycopeptides. 2) The sialic acid related oxonium ions 
(274 and 292) are more abundant in spectra of O-linked glycopeptides. 3) There is a clear 
difference in the normalized intensities of HexNAc related oxonium ions between N- and 
O- linked glycopeptides. Particularly, the intensity of 186 normalized by 204 is 
significantly higher in spectra of O-linked glycopeptides compared to those of N-linked 
ones.  
Spectral features can be used to distinguish spectra of N- and O-linked glycopeptides 
using machine learning. Here, we employed multinomial logistic regression classification, 
and trained and cross-validated this classifier on our curated spectral dataset of N- and O-
linked glycopeptides. The intensities of the nine aforementioned oxonium ions in Figure 
6-4 normalized by the intensity of 204 were chosen as the inputs to the classification 
algorithm. The use of the normalized intensities makes this approach more robust to 
change of platforms, as different manufacturers and instruments use distinctive units for 
ion intensities. Classification on this dataset of 1399 spectra from gp120, glycophorin A, 
ovalbumin and fetuin, yielded an accuracy of 98.8%, where the true ‘N-linked rate’ was 
99.7% and the true ‘O-linked rate’ was 97.3%. The classifier was additionally validated 
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on a second dataset of fetuin, glycophorin A and ovalbumin spectra with 94.4% accuracy. 
One of the advantages of using logistic regression is that in addition to classifying the 
spectrum, it provides the numerical probability of the classification being correct. This 
attribute is particularly crucial for the spectra that lie within the gray zone between the 
two classes of N- and O-linked. Looking at the statistics of the model coefficients, we 
observed that the most crucial feature for classification, as predicted, was the intensity 
ratio of 186 to 204 with a p-value close to zero. We hypothesize that, since O-linked 
glycans are richer in GalNAc, as opposed to N-linked glycans that are richer in GlcNAc, 
the change in the ratio of these HexNAc related spectra could point to the dissimilar ways 
that GalNAc and GlcNAc are fragmented. Halim et al showed that the intensities of the 
oxonium ions in glycopeptide tandem MS spectra help identify the glycan saccharide 
identities and in fact they demonstrated that the ratio of 186 to 204 oxonium ions is 
higher for GalNAc containing glycans compared to their GlcNAc containing counterparts 
[141], which is in line with our observation. 
The ability to predict the glycosylation type of a peptide based on its spectral features 
is beneficial in several ways. First of all, by breaking the search space into subspaces of 
N- and O-glycopeptides, the analysis could be performed almost twice as fast, which is a 
significant improvement in the execution time, especially for large datasets. Moreover, it 
can help distinguish the glycosylation type when the GPSM includes a glycan 
composition that belongs to both N- and O- glycan databases. For instance, the glycan 
portion of the glycopeptide corresponding to the spectrum in Figure 6-5 has the 
composition N3H3F0S0. As reported on the consortium for functional glycomics portal, 
this composition could potentially represent an N-linked or O-linked glycan (Figure 6-5). 
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The glycosylation classification model predicts this spectrum to match an O-linked 
glycopeptide with high probability (>99%). The peptide portion of this GPSM is in fact 
an O-glycosylated peptide (AHEVSEISVRTVYPPEEETGER) that belongs to 
glycophorin A and has three reported glycosylation sites. Therefore, in this example we 
know the prediction of the model to be true. This principle can be applied to predict the 
glycosylation type on peptides containing both N- and O-glycosylation sites. 
 
Figure 6-5. Prediction of the glycosylation type.   
The tandem MS spectrum corresponding to the following GPSM is shown: 
AHEVSEISVRTVYPPEEETGER – N3H3F0S0. The glycan composition of this GPSM can 
represent an N- or O-linked structure. The intensity of the oxonium ions, particularly the high 
ratio of 186 to 204 implies the glycosylation type to be O-linked, which is in agreement with the 
peptide sequence, as it lacks N-glycosylation sites and can only be O-glycosylated. 
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6.4.2    Identification of novel O-glycosylation sites on bovine fetuin 
Glycosylation of fetuin-A has been studied extensively using a variety of techniques such 
as beta-elimination for site-determination, and endoglycosidase digestion, HPLC and LC-
MS/MS with ETD or CID fragmentation for structure verification, [79], [87], [137], 
[142]–[144]. These studies have uncovered three N- (N-99, N-156, N-176) and six O-
glycosylation sites (S-271, T-280, S-282, S-296, T334, S-341) for fetuin-A as reported on 
the UniProt database. The sequence of fetuin-A (P12763) is given in Table 6-2 with the 
N- and O-glycosites shown in red and blue respectively and the peptides identified using 
GPQuest marked in green. As shown in Table 6-2, the reported glycosylation sites are 
covered by the peptides that have been assigned to tandem spectra of fetuin glycopeptides 
using GPQuest. The aa246-306 sequence starting with VTC and ending with LHR is a 
large glycopeptide consisting of 61 amino acids and harboring 4 of the reported O-
glycosylation sites, i.e. S-271, T-280, S-282 and S-296. The other two reported O-
glycosylation sites, T334 and S-341, were covered by aa334-348 or 
TPIVGQPSIPGGPVR. In addition to these reported sites, GPQuest was able to assign the 
aa313-333 (HTFSGVASVESSSGEAFHVGK) and aa307-333 
(AHYDLRHTFSGVASVESSSGEAFHVGK) sequences to several oxonium ion-
containing spectra with high confidence, revealing that these two peptides might in fact 
be glycosylated. The glycopeptide spectral matches corresponding to these peptides are 
shown in Table 6-2 along with the list of matching fragment b and y ions for each, which 
confirms the quality of the match between the glycopeptides and the tandem MS spectra.  
 
Table 6-2. Identification of novel O-glycosites on fetuin-A.  
Fetuin-A contains three N- (red) and six O-glycosites (blue) that have been reported in the 
literature. Identification of glycosylated forms of the aa313-333 and aa307-333 sequences in the 
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HCD fragmented fetuin tryptic digests suggest that this glycoprotein might harbor an O-glycosite 
on one or more of the following locations: T-314, S-316, S-320, S-323, S-324, and S-325. The 
GPSMs corresponding to these potentially O-glycosylated sites are listed in the bottom panel. 
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Both of the aforementioned sequences harbor S and T amino acids that could be 
potentially O-glycosylated. These amino acids are highlighted in magenta in Table 6-2. 
To evaluate the possibility of these peptides being glycosylated, the NetOGlyc tool was applied to 
the fetuin sequence to predict the possibility of mucin-type O-glycosylation at each site based on 
its sequence and surface accessibility [145]. The fetuin-A fasta file was submitted to the 
NetOGlyc 4.0 server for evaluation of the sequence for mucin-type glycosylation sites. The 
results of O-glycosite prediction of fetuin-A is shown in Figure 6-6. In this figure, the previously 
reported O-glycosites are marked by a green diamond, while the six potentially glycosites 
harbored by the aa313-333 sequence are represented by a magenta circle. From NetOGlyc 
predictions it appears that all of the S and T residues on the latter end of fetuin-A are highly likely 
 103
to be glycosylation. In fact, all of the thirteen S and T residues on aa271-357 are predicted to be 
modified by a mucin-type glycan with a chance of over 50%.  Of the thirteen sites shown in 
Figure 6-6, which only covers aa271-357 of the sequence, six sites have been previously reported 
and six are within the sequence of aa313-333, which is predicted to be O-glycosylated based on 
the GPQuest analysis. Among these six sites at positions of 314, 316, 320, 323, 324, and 325, S-
316 is the most likely O-glycosite with glycosylation probability of 90%. Targeted ETD 
fragmentation of the aa313-333 peptide could help identify the exact location of this novel 
glycosylation site on fetuin-A. 
 
Figure 6-6. Prediction of O-glycosylation sites on fetuin-A using NetOGlyc. 
The known O-glycosylation sites are marked by green diamonds while the potentially O-
glycosylated sites, as disclosed by GPQuest analysis, are marked by magenta circles. Based on 
predictions by NetOGlyc, all six potentially glycosylated sites are likely candidates with 
probabilities of glycosylation ranging from 54% to 90%. Among the six candidates, S-316 
appears to be the most likely glycosylation site with predicted glycosylation chance of 90%. 
6.4.3    Scoring of glycopeptide-spectral matches 
In order to understand how the scoring strategies affect the output of GPQuest, we 
analyzed and filtered three datasets of fetuin, glycophorin A and ovalbumin glycoproteins 
using the fragment ion count, Morpheus and intensity scores, and compared the outputs 
(Figure 6-7). The number of GPSMs for the three glycoproteins after applying 1%, 5% 
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and 25% FDR filters based on the three scores is plotted in Figure 6-7A. Based on this 
comparison, Morpheus and ion count scores appeared to be superior to intensity score in 
at least two out of three datasets, although Morpheus score slightly outperformed 
fragment ion count score in the number of identifications. It should be noted that in the 
ovalbumin datasets at FDRs of 1% and 5%, intensity score performed nearly as well as 
Morpheus score, suggesting that this scoring might provide an advantage in specific cases 
or datasets. We further compared the GPSMs assigned in the ovalbumin dataset at 1% 
using the three scoring systems, the results of which are shown in a Venn diagram in 
Figure 6-7B. Even though the overlap between GPSMs retuned by filtering based on 
intensity and Morpheus scores surpassed 80%, there remained to be 38 GPSMs that were 
only identified when the intensity score was applied. Upon further investigation of 
spectra corresponding to these 38 GPSMs, we observed that a common feature of these 
spectra is their sparsity of mass spectral peaks. An instance of a sparse spectrum is shown 
in Figure 6-7C. In fact, these spectra comprise of ions at fewer than average distinct 
mass/charge ratios, which tend to match well with the b and y fragment ions of peptides 
in the database, resulting in high intensity coverage. The sparse nature of these spectra 
could be due to low abundance of the precursor glycopeptide, or poor fragmentation. In 
either case, the intensity scoring creates an opportunity to identify these ions and increase 
identification and therefore we suggest it be used complementary to either Morpheus or 
fragment ion count scores. 
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Figure 6-7. Scoring of glycopeptide-spectral matches.  
A) The number of GPSMs is shown for filtering of ovalbumin, glycophorin A and fetuin datasets 
at 1, 5 and 25% FDR using fragment ion count, intensity, and Morpheus scores. In general, 
Morpheus and intensity score yielded the highest and lowest number of GPSMs, respectively. 
However, for the ovalbumin dataset, the intensity score was competitive with the other two scores. 
B) Further comparison of the ovalbumin GPSMs generated by the three scores at 1% FDR 
showed that there is considerable (>80%) overlap between the GPSMs of intensity and Morpheus 
scores. However, despite intensity score being inferior to Morpheus score in general, there were 
38 GPSMs that could only be identified using the intensity score. C) A representative spectrum of 
these 38 spectra is shown. The spectrum corresponds to N-glycosylated 
YNLTSVLMAM[Oxidation]GITDVFSSSANLSGISSAESLK. While only 4 ions were matched 
to this peptide, these ions covered ~50% of the total spectrum intensity (excluding the oxonium 
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ions). The intensity score was therefore effective in assignment of such a spectrum that suffers 
from poor fragmentation and subsequently, small number of matched ions. 
6.5    Discussion and conclusion 
This study presents a machine learning algorithm for distinguishing the type of 
glycosylation based on the spectral features of fragmented glycopeptides. This feature are 
integrated to precursor mass matching and spectral library matching algorithms for 
software-assisted glycoproteomics analysis of LC-MS/MS data using GPQuest. The 
algorithms incorporated into GPQuest are designed for analysis of HCD fragmented 
glycopeptides. HCD has proven to be a powerful technique for N-glycoproteomics 
analysis [43]; however, its application for assignment of O-glycopeptides is still limited. 
This is mainly due to the limitations of HCD for determination of the exact glycosite. 
ETD fragmentation is currently the gold standard for identification of intact O-
glycopeptides and the determination of the O-glycosites. The unique feature of ETD in 
breaking the amide bonds with minimal fragmentation of the post-translational 
modification makes it an excellent tool for studying PTMs and PTM sites. However, it 
should be noted that ETD has its own limitations. The quality of ETD fragmentation 
drastically deteriorates with decreases in charge state and increase in precursor ion mass. 
In fact, efficiency of ETD decreases for precursor ions with m/z > 1000 Da and charge 
states < 4 [146]. Glycopeptides, due to being modified by large glycans, tend to be in a 
higher mass range compared to non-modified peptides. In addition, sialic acid can 
decrease the average charge state of glycopeptides due to its negative charge and since O-
glycan are usually heavily sialylated, this characteristics particularly affects the charge 
state of O-glycopeptides. This could result in non-optimal fragmentation of O-
glycopeptides using ETD, which subsequently could compromise the quality of O-
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glycopeptide tandem MS spectra and reduce the sensitivity of O-glycopeptide detection. 
Therefore, the application of HCD for identification of O-glycosylated peptides could be 
greatly beneficial. In fact, we could take advantage of the superior sensitivity of HCD 
fragmentation in the glycopeptide mass range for determination of glycopeptide 
candidates for targeted glycoproteomics approaches using ETD. For example, using HCD, 
potentially novel O-glycosites were identified in this study that had gone amiss in prior 
ETD-based glycoproteomics approaches. 
Glycan oxonium ions patterns carry much information about the structure, size and 
composition of their precursor ions. This study focuses on using the intensity of these 
ions to predict the type of glycosylation in spectra of HCD fragmented glycopeptides. 
Theoretically, similar principles could be applied to project oxonium ion patterns back to 
the glycan structure that they represent. Building a spectral library of synthetic 
glycopeptides with known glycan compositions and structures would be an effective step 
to study the feasibility of glycan identification based on oxonium ions. This data could 
potentially lead into computational systems for relating the fragmentation pattern of 
glycans to their structures. In addition, the current study uses binary classification to 
predict the glycosylation type. In fact, the classifier divides the space of all possible 
oxonium ion intensity combinations into two subspaces of N- and O-linked glycosylation. 
In reality, other classes of glycosylation are possible. The sample preparation method in 
this study ensures that only glycoproteins are analyzed using LC-MS/MS. However, in 
general, other glycosylated forms such as proteoglycans, GPI anchors or glycolipids 
could be analyzed using LC-MS/MS and generate specific oxonium ion patterns that 
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Glycan imaging is a powerful technique for comparing glycosylation in cells of different 
origins within the same tissue section. Quantitative mass spectrometry imaging is an 
emerging area that combines quantitative mass spectrometry strategies with the concept 
of imaging to construct quantitative images of analyte distributions on tissue sections 
[147]. Quantitative imaging helps account for the inter-experimental variations and 
facilitates the comparison of glycan expression among multiple tissue sections. Current 
mass spectrometry imaging methods rely on label-free quantitation techniques or peak 
intensities. Therefore, the quantitation accuracy is subject to ionization interference of 
other co-existing ions. To achieve more reproducible quantification, isotopic or isobaric 
mass tags could be employed for tissue preparation. Derivatizing the terminal residues on 
glycans with isotopically labeled reagents provides a means for incorporating isotopic 
labeling into glycan structure for quantification.  
The N-glycan imaging strategy introduced in chapter 4 is restricted to non-sialylated 
glycans due to the labile nature of sialic acid, which are negatively charged terminal 
residues on N-linked glycans. There has been evidence to show that sialylation and 
branching of N-glycans changes in many diseases including cancer [148]–[150]. 
However, identification and quantification of sialylated glycans is challenging due to the 
post-source decay of sialic acids in mass spectrometry analysis. Various derivatization 
techniques have been developed for protection and quantification of sialylated glycans 
such as permethylation, amidation or esterification. These methods combined with 
isotopic labeling of glycans can be used for accurate quantification. Permethylation with 
light and heavy isotopes of methyl groups is an effective method for stabilization of sialic 
acid. However, the dependence of the subsequent mass shift between the light and heavy 
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mass peaks on the number of permethylation sites complicates the process of glycan 
quantification. Alternatively, labeling the reducing end of the glycans with light and 
heavy isotopes of reagents, resulting in fixed mass shifts between the pairs, can be used 
for quantification of glycans. However, these techniques fail to derivatize and protect the 
sialic acids. Shah et al have shown that labeling the sialic acid residues with light and 
heavy isotopes of p-toluidine combines some of the advantage of the two methods by not 
only stabilizing these residues, but also allowing for quantification of sialylated N-
glycans [65]. P-toluidine reacts with the carboxylic groups on sialic acids as well as 
aspartic acid and glutamic acid on the peptide backbone.  
The use of isotopic internal standards in quantitative MALDI imaging has been 
shown in previous studies [151]–[153]. This technique requires spiking or rather spraying 
a heavy isotope of the target analyte in a uniform layer over the tissue section. 
Introduction of internal standards improves the reproducibility and quantitation accuracy 
of the MALDI mass spectrometry results [154]. In situ labeling of proteins and sialylated 
glycans with light p-toluidine on the tissue and spiking heavy isotope p-toluidine labeled 
standards helps acquire quantitative mass spectrometry images of not only sialylated 
glycans but also peptides that contain aspartic or glutamic acids in their sequence  (Figure 
7-1). Our preliminary study shows that sialylated N-glycans can be effectively labeled 
with p-toluidine on FFPE tissue and detected using MALDI mass spectrometry. To 
demonstrate this, we labeled FFPE prostate tissue sections with light p-toluidine in the 
presence of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), 
released the N-glycans by PNGase F treatment, and profiled the glycans on MALDI-MS. 
The mass spectrum acquired from the labeled tissue along with that of a non-labeled 
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control section is illustrated in Figure 7-2. As shown in this figure, labeling of sialylated 
glycans with p-toluidine protects sialic acid residues from decay, and results in detection 
and identification of these glycans. In addition, p-toluidine neutralizes the negative 
charge of sialic acid residues, thus significantly improving the ionization efficiency of 
sialylated glycans [65]. This approach allows for accurate quantitative imaging of 
sialylated glycans and proteins without the need for synthetic heavy standards, which are 
expensive and for most glycans not commercially available.  
 
 
Figure 7-1. Isotope labeling with p-toluidine for glycan quantification.  
A) Labeling of glycoproteins with p-toluidine not only protects sialic acid from post-source decay 
but also allows for quantification of glycans and potentially peptides. B) Glycans or glycoproteins 
labeled with heavy mass tags are spiked into the sample as internal standards and provide a point 





Figure 7-2. In situ labeling of prostate tissue sections with p-toluidine improves detection of 
sialylated glycans. 
P-toluidine improves the detection of sialylated glycans using MALDI-MS by protecting the 
sialic acid residues from decay during sample preparation or ionization, and neutralizing the 
negative charge of these analytes, which diminishes the ionization efficiency of glycans in 
positive mode. 
 
A prospective application of the technologies introduced in this thesis is 
comprehensive profiling of glycosylation in clinical tissue samples by combining 
quantitative MALDI imaging of glycans and proteins with site-specific glycoproteomics 
analysis of the tissue sections. The proposed workflow is presented in Figure 7-3. First, 
intact glycoproteomics analysis are performed on the tissue sample by in situ tryptic 
digestion of the proteins followed by LC-MS/MS analysis of the collected peptides and 
GPQuest. This analysis would identify the intact glycopeptides in each tissue sample, 
which works as a guide for targeted imaging of the peptides and glycans of interest in the 
sample. To perform imaging of the glycans, or the peptides, an adjacent tissue section 
would be labeled with light isotope of p-toluidine, while an external sample, such as 
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serum will be labeled with heavy isotopes of p-toluidine to be used as internal standards. 
For this purpose, glycoprotein immobilization for glycan extraction (GIG) [26] and solid 
phase extraction of glycosite containing peptides (SPEG) [63] could be used for labeling 
and extraction of serum glycans and peptides, respectively. By applying the isotope-
labeled N-glycans or peptides from the serum over the target tissue section, as internal 
standards, one can achieve relative quantification between sialylated N-glycans or 
peptides among multiple tissue sections.  
 
Figure 7-3. Schematic workflow for quantitative imaging of glycans and peptides for 
comprehensive analysis of glycosylation in tissue sections. 
The intact glycopeptides of FFPE tissue sections can be identified by in situ tryptic digestion of 
proteins and glycoproteins directly on tissue and analyzing the extracts with LC-MS/MS and 
GPQuest. Adjacent sections can be labeled with p-toluidine for quantitative imaging of N-glycans 
and peptides. Integration of these results could be used to paint a more detailed picture of 
glycosylation on clinical FFPE tissue samples. 
 
It should be noted that introducing a complex sample as internal standard into the 
tissue sections could exacerbate the ion suppression effect, thus compromising the signal 
quality. An alternative solution to overcome this challenge would be to use single 
glycoprotein or glycopeptides such as sialylglycopeptide to extract isotopically labeled 
N-glycans or peptides as internal standards. Clearly, this alternative method would limit 
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accurate quantification to targeted N-glycans and peptides that are present in the standard 
glycopeptide or glycoprotein mixture. In addition, mass spectral peaks of glycopeptides 
might be shadowed by the more abundant peptides. Therefore, MALDI might fail to 
detect intact glycopeptides amongst all the analytes in the sample. In this case, LC-
MS/MS analysis is an alternative way to achieve quantitative information of the intact 
glycopeptides in the sample, though this would clearly compromise the spatial 
information of the tissue section. 
GPQuest has been applied to analysis of numerous samples such as recombinant 
glycoproteins and cancer cells and have provided invaluable information about 
glycosylation in these samples [2], [43], [47], [90]. Like any other software tool, the 
development and evolution of GPQuest is a process and optimization of some of its 
aspects and functions would improve the overall performance of this tool.  
GPQuest focuses on assignment of b and y ion fragments and intact peptide ions with 
partial fragments. After assignment of a tandem MS spectrum to a glycopeptide and 
despite a high match score, several peaks remain unassigned. It is likely that these peaks 
correspond to b and y ions with partial glycans or have resulted from loss of water or 
ammonia. Inclusion of these modification and glycopeptide fragment ions with multiple 
fragmentations would potentially improve the identification and scoring of glycopeptide-
spectral matches. In addition, assignment of these singular mass peaks might reveal more 
details about the structure of the glycopeptide such as information about the site of 
glycosylation. 
GPQuest has been developed for assignment of HCD tandem mass spectra of 
glycopeptides and thus benefits from superior sensitivity of HCD to ETD in the 
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glycopeptide mass range [146]. However, due to fragmentation of glycosidic bonds in 
HCD, the precise glycosylation site within the peptide is lost. ETD remains the most 
effective method for identification of the glycosylation site. HCD fragmentation of 
glycopeptides combined with GPQuest could be applied for narrowing down the pool of 
glycopeptides for targeted mass spectrometry analysis of glycopeptides of interest using 
ETD. Taking advantage of the superior sensitivity of targeted proteomics, this strategy is 
likely to result in characterization of more O-glycosylation sites. 
Glycoproteomics analysis is a computationally demanding task that involves handling 
of gigabytes of data. Cloud computing is a powerful technology, which is now accessible 
through resources such as Google cloud or Amazon web services. Our preliminary 
assessment of parallel processing and cloud computing for glycoproteomics showed that 
using parallel processing on 4 cores on a local machine or cloud computing on 12 cores 
on Amazon Elastic Compute Cloud (EC2) could expedite the simulations by ~4 and ~20 
times, respectively (Table 7-1). Based on this initial evaluation, integration of cloud 
computing in GPQuest would potentially improve the execution time and throughput of 
the process, especially since analysis of large datasets is the most time-consuming step of 
the glycoproteomics workflow. 
Table 7-1. Parallel processing and cloud computing expedites the glycoproteomics 
simulations using GPQuest. 
Number of Cores Core & Memory Simulation Time Comments 
1 (Local Machine) 3.7 GHz / 32 GB ~ 90 min No parallelization 
4 (Local Machine) 3.7 GHz / 32 GB ~ 20 min Requires MATLAB parallel 
computing toolbox  
12 (Amazon EC2) C3.8xlarge /60 GB ~ 5 min Requires MATLAB distributed 
computing server license  
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Isolation and identification of O-glycosite-containing peptides is an active area of 
research [83]. Using a sample-specific database of glycosite-containing peptides for 
precursor ion mass matching of spectral library matching using GPQuest improves the 
specificity of tandem MS assignment and increase the number of identified glycopeptides 
[43]. Moreover, the database of potentially O-glycosylated peptides, which comprises of 
all S/T containing peptides in the complete proteome database, is much larger than a 
sample-specific database and is computationally expensive. Forthcoming advances in 
sample preparation for enrichment of O-glycosite containing peptides are expected to 
improve the specificity, sensitivity and simulation time of glycoproteomics analysis using 
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